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ABSTRACT 
Encapsulated Interferon-Tau during Theiler’s Virus-Induced Demyelinating Disease: Efficacy of 
Treatment and Immune Response Profile. (December 2008) 
Dana Deanna Dean, B.S., Texas A&M University; M.S., Texas A&M University 
Co-Chairs of Advisory Committee: Dr. C. Jane Welsh 
                                                                   Dr. Robert C. Burghardt 
 
Multiple sclerosis (MS) is the most common primary demyelinating disease of the 
central nervous system in humans. Type I interferons are most frequently used to treat MS. 
However, their main mechanism of action remains elusive. Various biomarkers have been 
investigated for their ability to assess treatment efficacy, but results are often confounding due to 
differences in experimental design and variation in individual physiology.  In fact, not all MS 
patients respond to IFN therapy and a significant number suffer severe negative side effects and 
must cease treatment. Thus, alternative therapeutics that offer less cytotoxicity and greater 
efficacy are a major objective of research.   
This dissertation evaluated a novel type I interferon, interferon-tau (IFNT), and its 
ability to attenuate Theiler’s virus-induced-demyelinating disease (TVID), a mouse model of 
MS. In this model, viral infection with the BeAn strain of Theiler’s murine encephalomyelitis 
virus (TMEV) is the initiating factor leading to demyelination of the CNS. It was hypothesized 
that IFNT would: 1) provide therapeutic benefit as witnessed by a stabilization of clinical score, 
a decrease in CNS inflammation, and a decrease in CNS demyelination, and 2) shift the immune 
profile from a Th1 to a Th2 response.  
Once mice developed chronic disability, IFNT treatment began. This novel IFN was 
delivered in an innovative way: encapsulation (eIFNT) in an alginate polymer, which allowed for 
slow and sustained release. eIFNT was delivered by a 100 µl intraperitoneal injection  (i.p.)  
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containing 1.4M U of IFNT once every two weeks for 8 weeks. Mice were clinically scored 
weekly and BeAn-eIFNT mice demonstrated a decrease in clinical score. Bright field 
microscopy was used to evaluate CNS tissues where a decrease in demyelination and 
inflammation was noted in BeAn-eIFNT-treated mice. Ex vivo stimulation of virus-specific 
lymphocytes revealed an increase in both T helper 1 (Th1) and T helper 2 (Th2) cytokine 
production. Specifically, TNFA was produced at very high levels by splenocytes from BeAn-
eIFNT mice in response to UV-inactivated BeAn alone and in the presence of IFNT when 
compared to BeAn-eMOPS mice under the same conditions.  IFNG was produced at elevated 
levels from the splenocytes of BeAn-eIFNT mice versus BeAn-eMOPS mice when stimulated in 
vitro with UV-inactivated Bean and with BeAn in the presence of IFNT.  IL-2 was produced at 
moderately elevated levels from the splenocytes of BeAn-eIFNT mice versus BeAn-eMOPS 
mice when stimulated in vitro with UV-inactivated Bean. Il-2 was elevated to a statistically 
significant level (p<0.05) from BeAn-eIFNT mouse splenocytes when stimulated with BeAn in 
the presence of IFNT when compared to BeAn-eMOPS mice  and IL-10 was produced at 
elevated levels by splenocytes from BeAn-eIFNT mice versus that produced from BeAn-eMOPS 
mouse splenocytes in response to UV-inactivated BeAn alone and in the presence of IFNT. 
Quantification of T regulatory (Treg) cells in the spleen of eIFNT vs. eMOPS mice and blood of 
eIFNT vs. eMOPS mice revealed no difference between the two groups.  There was no statistical 
difference in virus-specific serum antibodies at the pretreatment time point noted in the OD 
readings of eIFNT mice at a dilution of 1/200 compared to the eMOPS mice. A modest decrease 
in the OD values at the 1/200 dilution were noted in the eIFNT mice compared to the eMOPS 
mice, but this difference was not significant. Antibody secreting cells (ASCs) from eIFNT mice 
versus eMOPS mice were slightly lower in the spleen and brains whereas there was a slight 
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increase in ASCs from the spinal cord of eIFNT mice when compared to those from eMOPS 
mice.  
 Altogether, the results support efficacy of the eIFNT treatment in the mice with TVID. 
Actual mechanisms of disease attenuation remain elusive at this time as mice exhibited an 
increase in certain Th1 and Th2 cytokines rather than the hypothesized shift from a Th1 to a Th2 
immune profile. Likewise, mice exhibited a modest decrease in virus specific antibodies as well 
as the number virus-specific ASCs which also refute the hypothesized increase in these values. A 
remarkable finding was the fact that immune cells derived from eIFNT treated mice appeared to 
be divided into two distinct types of biological responders although all of the mice responded to 
the in vivo treatment with a decrease in disease severity. It is hypothesized that this difference is 
a reflection of individual genetic variability in response to immune modulation which is 
surprising owing to the fact that the animals used for these studies are in-bred and considered to 
be as identical genetically as is feasible in a population of animals. Obviously, immune 
modulation can proceed through different mechanisms and still provide the desired result of a 
decrease in disease severity. However, this reality creates an added level of difficulty when one 
is trying to interpret biological data in order to determine whether a therapeutic regimen is 
efficacious within a patient population. 
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1. INTRODUCTION 
 
1.1. Multiple Sclerosis 
1.1.1. General Description of Multiple Sclerosis 
Multiple sclerosis was originally described by Charcot in 1868. There have been few 
revisions to the original description of the pathology of the disease process since that time. 
Multiple sclerosis (MS) is a human primary demyelinating disease affecting the central nervous 
system (CNS).  The etiology of MS is unknown, although viral infection during early 
adolescence is thought to initiate the disease (Acheson, 1977) and results in an autoimmune 
response that leads to demyelination over the next two decades of life in susceptible individuals. 
In support of this, many viruses have been isolated from MS brains including measles, mumps, 
parainfluenza type I (Allen and Brankin, 1993), human herpes simplex type 6 and Epstein-Barr 
virus (EBV) (Serafini et al., 2007). Currently, the most effective treatment for MS is interferon 
beta (IFNB), an antiviral agent, which has been linked to a decrease in the number of and 
severity of MS attacks (relapses).  
 
1.1.2. Immune-Mediated Pathogenesis of Multiple Sclerosis 
Prior to an episode of demyelination, immune cells, including T cells (CD4+ and CD8+), 
plasma cells, and macrophages, infiltrate the central nervous system (CNS) parenchyma and form 
perivascular cuffs (Prineas, 1985  Lucchinetti, et al., 2000). In fact, magnetic resonance  
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imaging (MRI) has been used to detect the presence of gadolinium-enhanced lesions as a direct 
measure of brain-blood barrier (BBB) disruption and predict a relapse (Barkhof and van 
Walderveen, 1999). Gadolinium is an extracellular contrast agent that is restricted from entry into 
the CNS by the BBB. Thus, its presence in the CNS during MRI is an indicator of BBB 
breakdown. This technique has become a vital tool in tracing and predicting lesions within the 
CNS of patients with MS.  As a result, both the number and volume of lesions that are 
gadolinium-enhanced correlate positively with the number and severity of new lesions upon 
relapse (Khoury et al., 1994; Miller et al., 1992).  Likewise, the absence of gadolinium-enhanced 
lesions on serial MRI is an indicator of lesion resolution, such as found during treatment regimes 
(glucocorticoid and IFNB). Once immune cells gain entrance to the CNS, the parenchyma 
surrounding the perivascular cuffs contain immune cell infiltration, myelin degradation and 
activated macrophages engulfing debris.  The number of macrophages and the amount of time 
they are present within a lesion are directly correlated with size and severity of the relapse 
(Prineas and Wright, 1978).  Although myelin destruction is often severe during the early stages 
of MS, the axons are minimally damaged.  However, as the disease progresses, axons are severed 
(Trapp et al., 1998) and this results in an increased incidence of irreversible disability. 
Neurologists now believe that patients with MS should commence treatment as early as possible 
to prevent permanent disability due to axonal loss. 
The BBB is formed by a continuous layer of cerebrovascular endothelial cells (CVE) 
sealed by tight junctions that limit permeability functions (Joo and Klatzo, 1989).  Also, there is a 
low level of major histocompatibility complex (MHC) expression on CVE, which limits their 
antigen presenting capacity under normal circumstances.  However, lymphocytic surveillance of 
the CNS parenchyma does occur in healthy animals (Wekerle et al., 1986), but only previously 
activated immune cells access the cerebrovascular endothelial cells of the BBB under normal 
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circumstances. Thus, activation in peripheral lymphoid tissues (lymph nodes and spleen) is 
critical for T cell access to CNS parenchyma. When the permeability of the BBB is compromised, 
a higher number of immune cells are allowed access to the nervous system parenchyma 
(Mokhtarian and Griffin, 1984). Additionally, when CVE express adhesion molecules and MHC, 
activated lymphocytes are able to transmigrate across the BBB. In MS, EAE, and TVID, 
inflammatory cell trafficking into the CNS increases dramatically. In fact, induction of EAE 
requires the injection of pertussis toxin (Voskuhl and Palaszynski, 2001) 24 and 48 hours after 
initial antigen priming with myelin components and Freund's complete adjuvant. This 'booster' of 
pertussis toxin causes BBB disruption and enhances the ability of myelin specific T cells to gain 
access to the CNS. Therefore, during EAE induction, BBB disruption is necessary for disease 
progression, while the TVID animal model of MS provides a more natural (not enhanced by 
experimental manipulations) course of disease onset and progression. Overall, therapies for MS 
are being sought that decrease inflammation within the CNS. One possible source of reducing 
pro-inflammatory cytokines and the subsequent inflammatory reaction are interferons which may 
also suppress viral activity, as in the case of TVID, where autoimmunity results from a persistent 
viral infection within the CNS.  Thus, decreasing viral replication via IFN treatment could allow 
the immune system to finally clear the CNS of the persistent virus or IFN treatment could 
decrease the intermittent production of virus that may trigger relapses. Either of these outcomes 
could produce disease resolution or reduce the number of future relapses.  
 
1.2. Theiler’s Virus 
1.2.1.     General Description of TMEV  
Theiler's murine encephalomyelitis virus (TMEV) is a natural pathogen of mice that 
causes an enteric infection, which occasionally reaches the CNS resulting in an encephalomyelitis 
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(Theiler, 1937).  There are several different strains of TMEV that produce different disease 
outcomes.  GDVII is a neurovirulent strain that, when injected intracranially (i.c.), results in fatal 
encephalitis in all strains of mice (Theiler and Gard, 1940).  BeAn and DA strains of TMEV are 
avirulent which, when injected i.c., result in a persistent infection that causes a demyelinating 
disease in certain susceptible strains of mice (SJL) that is similar to MS (Lipton, 1975). In fact, 
persistence of TMEV within CNS parenchyma is necessary for the development of TVID in 
susceptible strains of mice (Aubert et al., 1987).   
  
1.2.2.     Immunopathogenesis of TVID 
 There are two major animal models used to study MS: experimental allergic 
encephalomyelitis (EAE) and Theiler’s virus-induced demyelination (TVID). EAE is induced by 
immunizing mice or rats with brain homogenate or myelin components or by transferring myelin 
specific T cells from immunized mice into naive mice (Rivers et al., 1933; Soos et al., 1997). 
TVID has a viral etiology that culminates in autoimmune reactions to myelin components 
(Lipton, 1975; Borrow et al., 1998). Thus, TVID is an animal model in which demyelination is 
initiated by viral infection. 
During acute TMEV infection, T cells are the first to invade the CNS parenchyma (Dal 
Canto et al., 1995).  During the early phase of the disease, both CD4+ and CD8+ T cells mediate 
viral clearance and CD4+ helper T cells (Th2 subset) assist B cell differentiation into plasma cells 
which are probably the most important mediators of TMEV clearance (Welsh et al., 1987; Borrow 
et al., 1993) during the acute phase of TVID.  CD8+ T cells mediate viral clearance via their 
cytolytic capabilities or by producing IFNG. This evidence is supported by results from in vivo 
depletion experiments (Borrow et al., 1992) and studies with transgenic mice (Fiette et al., 1993; 
Pullen et al., 1993). CD8+ depleted mice developed more severe demyelinating disease than 
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immunocompetent controls (Borrow et al., 1992), most likely due to the elevated viral titers 
within the CNS which result in increased demyelinating disease.  
During late disease, both T cell subsets are involved in the development of lesions via 
TMEV-specific DTH reactions (Clatch et al., 1990), cytotoxic T cell reactivity (Rodriguez and 
Sriram, 1988), and myelin autoimmunity (Welsh et al., 1989; Welsh et al., 1990; Borrow et al., 
1998; Miller et al., 2001; Neville et al., 2002).  Thus, it is evident that T cells play a dual role in 
TVID.  In early phases of the disease, both CD4+ and CD8+ T cells mediate TMEV clearance, 
which is crucial to animal survival.  In late phases of the disease, the immunologic reaction is 
driven more toward a Th1 (cell-mediated inflammatory) response and T cells take on a 
pathogenic role causing tissue destruction with lesions similar in location and composition to 
those seen in MS (Friedmann and Lorch, 1985).  In order to cause myelin destruction, the T cells 
must first enter the CNS by transmigration across the BBB. Thus, understanding interactions 
between peripheral lymphoid organs, the BBB, and cells of the immune system should provide 
important insights into the mechanisms of pathogenesis during TVID. 
 
1.3. Type I Interferons 
1.3.1.   General Description of Type I IFN 
 Type I interferons (IFN) include five families. These are referred to as α, β, ω, τ, and 
δ (Alexenko et al., 2000). IFN delta is only found in pigs. IFN tau (IFNT) is only found in ‘true’ 
ruminants (Roberts et al., 1999) and is discussed later. Type I interferons range in molecular 
weight from 15-25kD depending on family member (α, β, etc.), species of origin (human and 
mouse being most germane to this proposal), genetic isoform, and amount of glycosylation 
(Oritani et al., 2001). All type I IFNs have a predominantly α-helical structure (5 helices) that is 
heat stabile, acid stable, and induced by viral infection (except for IFNT; see below). All Type I 
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interferons exhibit antiviral and anti-proliferative activities transduced through a common Type I 
IFN receptor (IFNAR-1 and IFNAR-2). The subunits of these receptors signal via the Jak-Stat 
system. IFNAR-1 is associated with Tyk-2 and IFNAR-2 is associated with Jak-1 protein tyrosine 
kinases. In basic terms, upon IFN binding to its receptor, Jak tyrosine kinases phosphorylate Stat 
proteins which dimerize and form a tri-molecular complex (ISGF-3) that transduces the signal to 
the nucleus where it binds and interferon response element to exert negative or positive regulation 
of DNA transcription (Levy et al., 2003). The most common gene products of IFN stimulation 
within a cell are interferon regulatory factors (IRFs), myxovirus resistance protein A (Mx A), and 
2’-5’-oligoadenylate synthetase (OAS) (Oritani et al., 2001). The IRFs primarily autoregulate 
subsequent IFN production (Paun and Pitha, 2007). MxA and OAS are key molecules in the 
induction of an antiviral state in cells exposed to Type I IFNs.  Thus, due to their ability to inhibit 
both cellular proliferation (especially cells of the immune system) and viral replication, Type I 
IFNs have been assessed for their value for treatment of a variety of diseases (MS, rheumatoid 
arthritis, Hepatitis C infection, herpes simplex infection). 
 
 
1.3.2.    Use of IFNB in the Treatment of Multiple Sclerosis  
Although MS was originally described 140 years ago, first line treatment options were 
only recently approved by the Federal Drug Administration (FDA). In 1993, the results of the first 
clinical trial of an IFN (IFN-β1b) for the treatment of MS (The IFNβ Multiple Sclerosis Study 
Group, 1993) demonstrated a decrease in the number and severity of MS attacks in the treatment 
group. Currently, there are three Type I interferons classified as first-line therapeutics for use in 
relapsing/remitting (80% of all MS patients) and secondary progressive (15% of all MS patients) 
forms of MS (reviewed in Bayas and Gold, 2003). The original clinical trials enlisted IFNB-1b, 
known commercially as Betaferon®/Betaseron®. More recently, there are two IFNB-1a forms, 
 7
known commercially as Avonex® and Rebif®. These three formulations differ in their routes of 
delivery (s.c. versus intramuscular), frequency of delivery (daily, 1 X/week, 3 X/week) and 
dosage (6 MIU, 8MIU, 12MIU). These three IFNs modify the number of relapses a patient has 
during an extended time period and slow progression of the overall disabilities that accumulate in 
MS patients over time. Currently, researchers agree that the sooner that IFN treatment 
commences, the better its treatment efficacy (Söderström 2003). The two most common side 
effects in MS patients are flu-like symptoms and injection site reactions (Lublin and Reingold, 
1996; Mehta et al., 1998). These side effects can result in a patient having to withdraw from an 
IFN treatment regimen. Injection site reactions are caused by production of antibodies to the IFN 
molecule that begin to neutralize the IFN and cause the patient to become a ‘biological non-
responder’. The percentage of patients producing neutralizing antibodies in clinical trials 
(reviewed in Bertolotto et al., 2004) ranges from 2% (Avonex) to 50% (Betaferon/Betaseron). 
These differences in antibody production to commercial IFNs is based on the product itself (and 
how it is manufactured), as well as route of administration, dose, and frequency of dose. 
Therefore, a less antigenic and less toxic (flu-like symptoms and lymphopenia are indicative of 
toxicity) IFN would be ideal. Likewise, an IFN treatment with increased benefits (such as 
remyelination) to a broader range of MS patients (less biological non-responders) would further 
enhance the current situation of MS patients.  
 
 
1.3.3.     Type I Interferons in TVID 
Type I IFNs are known to be vital in early viral clearance of Theiler's virus since Type I 
IFN receptor knock out mice died early after infection (Fiette et al., 1995). Only one study has 
used Type I IFNs in the TVID model.  During the late demyelinating phase of TVID, the 
administration of Type I interferons, IFN-A/B, to SJL/J mice infected with the DA strain of 
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Theiler's virus, resulted in increased demyelination when given 4.5 months p.i                               
for 16 weeks (Njenga et al., 2000).  IFNA/B given for the short term (5 weeks of treatment) 
resulted in the promotion of remyelination.  The authors noted that the mice lost weight during 
weeks 6-7 of treatment, developed reduced DTH responses to TMEV and decreased numbers of 
T and B cells infiltrating the CNS. No studies have been done on the treatment efficacy of IFNT 
with the TVID model. 
 
1.4. Interferon-tau 
1.4.1.     General Description of IFNT 
IFNT is produced by mononuclear trophectoderm of conceptuses of pecoran ruminants 
(sheep, bovine, giraffes, and goats). It was originally discovered as a product of sheep conceptus 
trophectoderm (Godkin et al., 1982) and is the maternal recognition signal for pregnancy in sheep 
(Bazer and Johnson, 1991). IFNT rescues the corpus luteum by inhibiting luteolysis, thereby 
maintaining progesterone levels and pregnancy. It also induces production of interleukins-4 (IL4) 
and -10 (IL10), Th2 cytokines, within the uterine environment during early pregnancy. These two 
cytokines suppress delayed type hypersensitivity (DTH) responses, which if uncontrolled would 
lead to immune rejection of the conceptus.  
 
1.4.2.     IFNT as a Treatment in EAE 
 Extensive research has been conducted using IFNT over the past 15 years. When 
compared with IFNA and IFNB, IFNT has many of the same beneficial properties of other Type 
I interferons (antiviral and antiproliferative) without the side effect of cytotoxicity in vitro 
(Pontzer et al., 1991; Assal-Meliani et al., 1993) or fever, weight loss, and flu-like symptoms in 
vivo (Soos and Johnson, 1999). Most importantly, IFNT is effective in the prevention and the 
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treatment of EAE disease progression even when challenged by superantigens (Soos et al., 
1995). The ability of IFNT to be cross-species reactive (Khan et al., 1998; Martal et al., 1998; 
Assal-Meliani et al., 1993) is crucial to its use for treatment of human autoimmune diseases, 
such as MS. It has been successfully tested for cytotoxicity in bovine, porcine, ovine, murine, 
and human cell lines. Also, acute and chronic forms of EAE were prevented whether IFNT was 
administered orally or intraperitoneally (Soos et al., 1997). Oral administration is highly desired 
since many MS patients develop neutralizing antibodies to IFNB during the first year of 
administration which can result in loss of treatment efficacy (Bertolotto et al., 2004). With oral 
administration in mice, no antibodies were detected against IFNT.  IFNT treatment of EAE also 
resulted in increased IL-10 levels and has been proposed to explain the mechanism of action of 
IFNT (Mujtaba et al., 1997).  The importance of IL-10 in EAE has been shown in transgenic 
mice.  IL-10 deficient mice develop more severe EAE and IL-10 over expressors were 
completely resistant to disease (Bettelli et al., 1998). Soos et al. (1997) also found increased 
levels of IL-10 in IFNT-treated mice and increases in transforming growth factor beta (TGFB) 
has also been reported (Khan, et al., 1998). This is very encouraging because a generally 
accepted goal of MS treatment is to attenuate a Th1 (proinflammatory) immune response by 
shifting to a Th2 suppressive cytokine profile (Baker et al., 1996).  
Although the efficacy of IFNT has been tested in the context of the EAE model, an 
evaluation of its therapeutic value has not been investigated in a virus model of demyelinating 
disease.  Thus, the current investigations are needed to fill this void within the Type I IFN 
literature. 
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1.5. Possible Mechanisms of Disease Modifying Drugs 
1.5.1. Th1/Th2 Cytokine Profiles  
The normal functioning immune system is thought to be in balance between a Th1 and 
Th2 type immune response. The cytokine environment encountered upon antigen activation 
polarizes a CD4+ T cell to become either a Th1 or Th2 type cell (Kaiko et al., 2007). CD4+ Th1 
cells are the predominant cell type associated with disease pathology in MS and TVID. 
Polarization to a Th1 subtype is driven by IL-12 produced by antigen presenting cells (Kaiko et 
al., 2007 and Dittel 2007). Upon activation by MHC-II-antigen complex bound to an APC, the 
Th1 cell secretes IFNG. IFNG is the cytokine most commonly identified as the hallmark 
cytokine of the Th1 profile. Its major effect is the stimulation of macrophages which further 
enhance the Th1 cell’s polarization. IL-2 is also produced by the Th1 cell as a growth factor for 
naïve cells and a survival factor for activated Th1 cells. Overall, the Th1 cytokine profile drives 
a cell-mediated immune response which is important in eradicating intracellular pathogens and 
tumor cells.  
CD4+ Th2 cells produce a cytokine profile that drives humoral immunity through 
activation of B cells and the subsequent production of antibodies. IL-4 is the hallmark cytokine 
of the Th2 profile. Its major effect is to induce immunoglobulin class switching in activated B 
cells. IL-5, IL-10, and IL-13 are also associated with humoral immunity and act on various 
components of the innate immune system (eosinophils and mast cells) to assist in the eradication 
of extracellular organisms, such as parasites.  
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1.5.2. Th1 Suppression  
Cytokines secreted by Th2 cells that suppress Th1 responses include IL-4, TGFB, and IL-
10 (Arnason and Reder 1994). During remission of MS, patients’ white blood cells produce 
increased levels of TFGB.  Likewise, TVID is ameliorated by TGFB treatment (Drescher et al., 
2000).  PGE2 is secreted by macrophages and has inhibitory effects on a Th1 response as well. It 
appears to act as a self-regulator for macrophages in that PGE2 and IFNG show inverse 
production rates. IFNT, in sheep, favors PGE2 production over PGF2a (Hansen et al., 1999) within 
the uterine environment during pregnancy, which is vital to maintaining the corpus luteum in 
early pregnancy. If this mechanism of action occurs during TVID treatment with IFNT, then it 
could provide a positive effect of IFNT treatment via down-regulation of macrophage activity. 
Results from our laboratory have shown that IFNT increases MHC Class I expression and 
decreases IFN-γ induced MHC Class II expression on cerebrovascular endothelial cells 
(Tennakoon et al., 2001). This is additional evidence of a switch from a Th1 response to a Th2.  
The expression of MHC Class I is important for antiviral activity during infection. However, 
MHC Class II allows CD4+ Th1 cells to drive the cell-mediated response leading to more 
destruction in MS, EAE, and TVID. By suppressing MHC Class II, the immune response should 
favor a switch to a Th2 response and suppression of the destructive Th1 immune response. 
Overall, the suppression of a Th1 immune response, whether via a switch to a Th2 profile or 
through mechanisms provided by Tregs, is the common goal of MS therapies and the common 
criteria for studying mechanisms of disease amelioration during TVID. 
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1.5.3. T-regulatory Cells  
Historically, there has been much debate about the existence of a CD4+ T-cell that 
provides a regulatory (suppressive) mechanism within the immune system. In the past four years, 
the T regulatory cell (Treg) has been accepted as a vital part of the normal functioning immune 
system.  Sakaguchi and colleagues revitalized the issue of Tregs in the mid 90’s when they 
described the CD4+CD25+ T cell phenotype as being important in maintaining self-tolerance 
(Sakaguchi, et al., 1995).  Without the presence of this population of T cells, animals would 
succumb to a variety of spontaneous autoimmune diseases. Transfer of the CD4+ CD25+ T cell 
population into these immunocompromised mice could inhibit the formation of the autoimmune 
disorders. Since their phenotypical identification, research has focused on the ability of these cells 
to maintain self-tolerance and confer graft tolerance in new hosts, as well as their ability to 
suppress tumor immunogenicity (Sakaguchi, et al., 2001; McHugh and Shevach, 2002). A more 
recent addition to the Treg specific phenotype is the expression of forkhead box protein 3 (Foxp3) 
which is a transcription factor that is linked to the development and function of the Treg 
population (Fontenot et al., 2003 and Hori et al., 2003). Currently, the CD4+ CD25+ Foxp3+ T 
cell is the accepted phenotype for a Treg. There are two types of Tregs recognized:  naturally 
occurring Tregs (nTregs) that are produced in the thymus and inducible Tregs (iTregs) that are 
primed during an inflammatory response (Shevach, 2002). A common link between these two 
cells is the need for IL-2 (Yarkoni et al., 2008). Naturally occurring Tregs are not able to produce 
IL-2, but it is necessary for maintenance of suppressor phenotype. Inducible Tregs need IL-2 and 
TGFB to achieve the suppressor phenotype (via Foxp3 expression), but unlike nTregs, they are 
able to produce their own IL-2 once differentiated. IL-2 is necessary for iTregs to maintain their 
suppressor functions as well. Both types of Tregs need antigen for stimulation (Horwitz et al., 
2008). Self antigens stimulate nTregs whereas foreign antigens stimulate iTregs. Both types of 
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Tregs can induce suppressive activity in CD4+CD25- T cells in the presence of TGFB and IL-10 
(Zheng et al., 2004). Therefore, IL-2, TGFB, and IL-10 are crucial for the generation and 
maintenance of all Tregs. By using IL-2, Tregs compete with Th1 cells for survival. Additionally, 
Tregs produce IL-10 and TGFB which is a mechanism of suppressing Th1 cell activities (Yarkoni 
et al., 2008). The effect of Treg activity can be beneficial or detrimental to an animal depending 
on the immune response being suppressed by these cells. During TVID and MS, inflammatory 
cell infiltrates are damaging self-antigens (myelin) within the CNS. CD4+ Treg function has been 
shown to be defective in MS patients during a relapse, but the function is restored upon remission. 
Tregs have been shown to decrease IFN-γ levels secreted by macrophages from MS patients 
(Arnason and Reder, 1994).  Therefore, the TVID model is a valuable tool for testing the 
therapeutic potential of manipulating the Treg population in order to suppress a Th1 response as is 
seen in MS. 
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2.  ATTENUATION OF TVID WITH ENCAPSULATED IFNT: DECREASES IN 
CLINICAL SCORE, CNS INFLAMMATION AND DEMYELINATION 
 
2.1. Introduction 
 The need for efficacious treatments for MS patients is still an active area of research. 
Currently, three of the five most commonly used therapeutics in MS patients are Type I 
interferon therapies. These include Avonex® (2006, product insert) and Rebif® (2005, product 
insert) which are IFNB1a and Betaseron® (2003, product insert) which is IFNB1b. The route of 
administration, dosage, and frequency of treatment differ among the three IFN therapies 
(McDonagh, et. al., 2007). Avonex® is administered intramuscularly (i.m.) once a week at a 
dose of 30 micrograms (µg). Rebif® is administered subcutaneously (s.c.) at a dosage of 22 µg 
or 44 µg three times a week. Betaseron® is given s.c. every other day at a dosage of 250 µg.  All 
three agents are recommended for RRMS. Additionally, Betaseron® is the approved treatment 
for SPMS. 
 Usage of IFNB results in adverse side effects in the majority of MS patients. The most 
common side effects are flu-like symptoms and include fever, myalgia, fatigue, and weight loss 
(Lublin and Reingold, 1996; Mehta et al., 1998). These side effects can be so pronounced in 
some individuals that IFNB treatment must cease. Another common side effect is injection site 
reaction. This is caused by the production of antibodies to the IFN treatment and can lead to 
neutralization of the IFNB. If the antibodies to the IFNB are neutralizing in nature, then the 
therapeutic benefit of the IFN treatment is lost and a patient becomes a non-responder.  
Neutralizing antibodies results in loss of therapeutic efficacy which is a common problem in 
protein-based therapies and is an important area of drug manufacturing.  
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The fact that IFNT exerts an effect across species and that the toxicity associated with 
IFNT is far less than that associated with other Type I interferons, has prompted investigations 
directed towards unraveling the value of IFNT as a highly desirable therapeutic agent.  
Therefore, the objectives of the current study are simplistic in nature: to demonstrate drug 
efficacy. It is hypothesized that IFNT treatment will result in: a) a stabilization in the clinical 
scores of mice upon treatment with IFNT; b) a reduction in inflammation and/or demyelination 
within the CNS of mice treated with IFNT; and c) evidence of tolerability (lack of toxicity) in 
mice treated with IFNT. For these studies, the novel IFNT was administered in an innovative 
way, i.e. by encapsulation in an alginate polymer. This innovation allows for slow, constant 
release of the IFNT while decreasing the number of injections needed for treatment purposes. 
The eIFNT was administered by i.p. injection of 100µl of capsules containing 1.4 MU/100 µl of 
IFNT. The estimated rate of release was 105 U/day. It is suggested that this mode of 
administration could provide greater benefits by reducing the stress caused by multiple injections 
within the mice and by providing a constant release of the IFNT. 
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2.2. Materials and Methods 
2.2.1. Virus Stocks 
 
  The BeAn strain of TMEV was a gift from Dr. H. L. Lipton (Northwestern University, 
Evanston, IL.)  The virus was propagated in BHK-21 cells, titered, aliquoted, and stored at -80o 
C before use (Welsh et al., 1987). 
 
2.2.2. Animal Infection   
 
 SJL/J mice were purchased from Harlan (Indianapolis, IL) and bred in-house. Twenty-
eight day old female mice were anesthetized with Isoflurane (Vedco, Saint Joseph, MO) and 
inoculated intracranially (i.c.) into the right cerebral hemisphere with 20 µl of BeAn strain of 
TMEV (5 X 105 plaque forming units) suspended in media or 20 µl of PBS alone. The SJL/J 
mice were divided into two groups as follows: 21 received PBS only and 58 received 5x105 
plaque forming units (pfu) of BeAn virus. The day of i.c. inoculation was considered day 0. All 
animal protocols were in accordance with NIH Guidelines for Care and Use of Laboratory 
Animals and were approved by the Texas A&M University Laboratory Animal Care and Use 
Committee. See Figure 1 for experimental design. 
 
2.2.3. IFNT 
 
IFNT was a gift from Dr. Fuller W. Bazer (Texas A&M University, College Station, 
TX). IFNT was isolated as previously described in Ott et al., 1991. The protein concentration 
was determined to be 1mg/ml by the Lowry assay (Lowry et al., 1951) and 108U/ml by virus 
plaque assay. 
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Figure 1. Experimental design: Section II. The following schematic denotes BeAn or PBS infection time 
point (green arrow), treatment (eIFNT or eMOPS) administration time points (blue arrows), and blood 
collection time points (red asterisks). Time points are in weeks post infection. 
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2.2.4. IFNT Encapsulation 
 Alginate capsules were prepared as previously described with some modifications 
(Abraham et al., 1996; Arenas-Gamboa et al., 2008). Briefly, 1 ml of 108 U/mg of IFNT was 
mixed with 5 ml of alginate solution (1.5% sodium alginate, 10 mM MOPS, 0.85% NaCl [pH 
7.3]). Spheres were obtained (See Figure 2) by extruding the suspension through a 200 µm 
nozzle into a 100 mM calcium chloride solution and stirred for 15 min by using an Inotech 
Encapsulator I-50 (Inotech Biosystems International, Rockville, MD). After extrusion of the 
IFNT-alginate mixture into the CaCl2, the capsules were washed twice with MOPS for 5 min and 
further cross-linked with 0.05% poly-L-lysine (molecular weight: 22,000; Sigma-Aldrich, St. 
Louis, MO) for 10 min. After two successive washes, the beads were stirred in a solution of 
0.03% (wt/vol) alginate for 5 min to apply an outer shell and washed twice with MOPS. VpB 
was added to the shell of the capsule (vjbR::Tn5/VpB/shell) as a cross-linking agent by the 
addition of VpB in an equimolar ratio of poly-L-lysine/VpB. After two successive washes, beads 
were collected, aliquoted (600 µl capsules in 900 µl of MOPS buffer) and stored at 4°C.  
Capsules (Figure 3) were kept at 4°C in the presence of excess IFNT until time of 
injection. Before injection, capsules were rinsed 3X in MOPS by resuspending capsules and 
allowing them to resettle. Finally, capsules were resuspended in the appropriate amount of 
MOPS buffer prior to injection (900µl). 
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Figure 2. IFNT encapsulation apparatus. The IFNT solution enters the encapsulator via a syringe attached 
to the filtered port on top of the glass chamber. As the IFNT solution enters the apparatus it passes through 
a metal plate where it encounters an electrostatic charge as well as a vibrational frequency.  This causes 
the stream of IFNT solution to form spheres that contain IFNT.  The capsules are rinsed several times to 
remove any excess IFNT solution. The eIFNT is collected and stored at 4°C in excess IFNT to inhibit 
release from the capsules until needed.  
 
 
 
 20
 
Figure 3. Alginate capsules containing IFNT or MOPS buffer. The capsules were stable for three months 
at 4°C. The images above show capsules after 24hrs at 4°C, after passage through a 23G needle, and after 
4 weeks at 4°C 
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2.2.5. IFNT Treatment of Mice 
 
             Beginning at 11 weeks p.i., a 100 µl i.p. injection of encapsulated IFNT (eIFNT) was 
given every two weeks for a total of eight weeks. An estimated dose of 105 units of IFNT (Soos 
et al., 1995) was released daily from the capsules. Capsules containing MOPS buffer (eMOPS) 
were used as a vehicle control treatment. The treatment groups included: BeAn-infected/eIFNT-
treated (n=18), BeAn-infected/ eMOPS-treated (n=18), and PBS mock infected/eIFN-treated 
(n=18). 
 
2.2.6. Clinical Scores 
Mice were weighed and evaluated weekly and assigned a clinical score based on disease 
severity. Mice were graded on overall body condition, posture, balance, front and hind limb 
spasticity, and activity level. Clinical scores were based on a scale from 0-6, where 0 indicates a 
healthy animal and 1-6 represent gradually increasing severity of signs as follows: 1:piloerection 
and/or hunched posture with slight gait abnormalities; 2: piloerection and lowered or hunched 
posture plus unsteady gait; 3: very unsteady gait, weak grasp response when placed on wire grid, 
decreased activity level, and occasional slight limb monoparesis; 4: severe hind limb weakness 
and/or spastic paralysis, weight loss, severe decrease in activity level, and loss of the righting 
response; 5: paraparesis of hind limbs and forelimbs, severe weight loss, incontinence, and 
complete loss of righting response; 6:  highly moribund/dead (Borrow et al.,1998).  For these 
observations, animals were examined while walking on a metal grid.  The metal grid permitted 
inspection of an animal's movements from all sides (top, bottom, left and right side) allowing for 
close scrutiny of possible deficits.  An inclined area was used to test an animal's balance and 
strength while ascending or descending. 
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2.2.7. Perfusion and Tissue Dissection for Paraffin Embedding 
 
Mice were euthanized with 150 mg/kg of Beuthanasia-D special (Schering-Plough 
Animal Health, Boxmeer, The Netherlands) and perfused via the left ventricle with 4% 
paraformaldehyde in 1X PBS.  The brain and spinal cord were dissected out and immersed in the 
same fixative.  After an18-hour incubation in paraformaldehyde, tissues were rinsed once in 
PBS. Spinal cords were removed from the vertebral column and cut into 9 sections: 3 cervical, 3 
thoracic and 3 lumbar. Brains were removed from the skull and cut into 3 sections in order to 
view the brain stem, pons, and cerebellar regions of the brain. Tissues were placed in cassettes 
and stored in PBS until ready for processing and embedding in paraffin. Once CNS tissues were 
removed, the remainder of the body was placed into a 50 ml conical tube and immersed in 
formalin and stored at 4°C until a full necropsy could be done.  
 
2.2.8. Sectioning/Staining of Paraffin Embedded Tissues 
For spinal cords, blocks from each animal (n=6 for each treatment group) were sectioned 
at 5 µm and stained with hematoxylin and eosin (H&E) to observe inflammation and Luxol Fast 
Blue (LFB) to determine demyelination.  Six slides were made from each spinal cord block with 
a minimum of 20 µm skipped between sections. The first slide and the last slide of each set were 
stained with LFB while the other four slides were stained with H&E.  
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2.2.9. Perfusion and Processing for Resin Embedding 
Mice were euthanized with 150 mg/kg of Beuthanasia-D special (Schering-Plough 
Animal Health, Boxmeer, The Netherlands) and perfused via the left ventricle with 2% 
paraformaldehyde:3% glutaraldehyde in 0.1 M sodium cacodylate.  The brain and spinal cord 
were dissected out and immersed in the same fixative.  After an18 h incubation in the fixative, 
spinal cords were removed from the vertebral column and cut into 9 sections: 3 cervical, 3 
thoracic and 3 lumbar. Dissected tissues were rinsed 3x in 0.1 M sodium cacodylate and post-
fixed in osmium tetraoxide overnight. Tissues were rinsed 5x in 0.1 M sodium cacodylate and 
dehydrated through a graded series of ethanol, followed by propylene oxide. After dehydration, 
tissues were infiltrated overnight with resin. Tissues were embedded in beem capsules and resin 
was polymerized at 60ºC for 72 h.  
 
2.2.10. Sectioning/Staining of Resin Embedded Tissues 
For spinal cords, blocks from each animal (n=6 for each treatment group) were sectioned 
at .3 µm and stained with 1% toluidine blue.  Two slides were made from each spinal cord block. 
Nine blocks were sectioned for each animal.  
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2.2.11. Microscopic Evaluation of Paraffin and Resin Embedded Tissues 
 
Spinal cord tissues from the cervical, thoracic and lumbar levels were examined and 
scored based on the degree of demyelination within the cervical, thoracic, and lumbar regions 
and the amount of inflammation within the various dorsal, lateral, and ventral funiculi and/or 
meninges. A pathologic score of 0-4 was assigned to each section according to the following 
criteria: Stage 0= no lesions; Stage I=extremely mild, marginally identifiable inflammation, no 
demyelination (<5% of area affected); Stage II=mild, definitive inflammation with some 
demyelination, focal and limited in scope,(5-10% of area affected); Stage III=moderate 
inflammation and demyelination, multi-focal and moderately extensive in scope (25-50% of area 
affected); Stage IV=prominent inflammation and demyelination, moderate tissue destruction, 
multi-focal and prominently extensive in scope (50-75% of area affected); Stage V=very 
prominent demyelination with or without inflammation, severe tissue destruction, multi-focal 
and very prominently extensive in scope (75-100% of area affected).  A mean score was derived 
for each animal. Individual animal means were pooled within treatment groups (n=12) to 
calculate means used in graphical representations.  
 
2.2.12. Statistical Analysis 
All data were reported as means ± standard error (SEM). Graphpad Prism 5.0 software 
generated all graphs and analyzed all data. Analysis of variance (ANOVA) was used for all 
parametric measurements, followed by Bonferroni post-hoc procedure when appropriate. 
Kruskal-Wallis Rank Sum was used for all nonparametric data. The confidence interval was set 
at 0.05 for all analyses. 
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2.3. Results 
2.3.1. Mice Treated with IFNT Showed a Significant Decrease in Clinical Score, but No 
Difference in Body Weights. 
 The most obvious early indication of treatment efficacy was demonstrated when mice 
regained their normal posture while at rest as well as during ambulation. After two weeks of 
eIFNT treatment, mice began to show a decrease in clinical score (Figure 4). This decrease 
continued for the entire 8 week treatment period.  Mice that received eMOPS had an increase in 
clinical score over the eight week treatment period (p<0.001). As shown in Figure 5, all of the 
eIFNT mice showed a decrease in clinical score after eIFNT treatment. The majority of Bean-
eIFNT mice (28/30) showed a substantial decrease in clinical score of at least one point. Most 
BeAn-eIFNT mice (21/28) showed a decrease of 1.5-2 points. The majority of the BeAn-eMOPS 
mice (22/26) had an increase in clinical score of at least one point during this same time frame. 
PBS mock-infected mice showed no clinical signs and are not represented on Figures 3 and 4. 
There was no difference seen in the body weights of the BeAn-eIFNT-treated mice compared to 
the BeAn-eMOPS-treated mice (Figure 6).  Once again, data for PBS mice are not shown. 
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 Figure 4. Clinical scores of mice decreased during eIFNT treatment. Mice were scored weekly starting at 
9 weeks p.i.  At 11 weeks p.i., BeAn-infected mice were treated with eIFNT (green squares) or eMOPS 
(blue circles) for eight weeks. A decrease in clinical score was evident the second week of treatment and 
continued for the duration of the treatment period. Results are combined means of five individual 
experiments with 6-7 mice in each group. Data from PBS controls are not shown. P < 0.001. 
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Figure 5. Difference in clinical scores of individual mice treated with eIFNT. Differences in pre-treatment 
and post-treatment scores demonstrate the efficacy of eIFNT treatment (green bars) versus eMOPS 
treatment (blue bars) in TVID mice. Post-treatment scores of individual mice at 20 weeks p.i. were 
subtracted from the pre-treatment clinical scores at 11 weeks p.i. A negative result indicates a clinical 
score that was higher at the post-treatment time point. All BeAn-eIFNT (green bars) mice had a reduction 
in clinical scores at the post-treatment time point, reflected graphically as a positive difference. All but one 
BeAn-eMOPS mouse (blue bars) had increased clinical scores, reflected graphically as a negative 
difference. 
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Figure 6. Body weights were not different between treatment groups. Mice were weighed weekly to 
monitor body condition. There were no differences in average body weight between the BeAn-eIFNT 
(green squares) treated mice and the BeAn-eMOPS (blue circles) treated mice. Results are shown as 
combined means of five individual experiments with 6-7 mice in each group. PBS controls are not shown. 
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2.3.2. Mice Treated with eIFNT Showed a Decrease in Inflammation and Demyelination. 
 Paraffin-embedded spinal cord sections were stained with H&E and LFB to determine 
extent of inflammation and demyelination (Figure 7 A-D). Resin-embedded spinal cord sections 
were stained with toluidine blue (Figures 8A and 8B) No demyelinating lesions were noted in 
the BeAn-eIFNT mice (Figures 7A and 7B; Figures 8A and 8B). Occasionally, minimal 
inflammation was noted in the meninges, but these inflammatory cells affected <2% of the 
meningeal area. The BeAn-eMOPS mice had definitive demyelinating lesions (Figures 7C and 
7D; Figures 8C and 8D) and showed pronounced inflammation (Figure 7C) of the meninges as 
well as perivascular cuffing. Figure 9 shows the graphical representation of the histopathological 
scores of the BeAn-eIFNT, BeAn-eMOPS, and PBS-eIFNT mice. The amount of 
inflammation/demyelination of BeAn-eMOPS mice was significantly higher (p< 0.05) than 
BeAn-eIFNT mice. BeAn-eMOPS mice exhibited histopathology significantly higher (p< 0.01) 
than PBS-eIFNT mice. BeAn-eIFNT mice and PBS-eIFNT mice did not exhibit differences in 
histopathology scores. Brain tissues were examined and modest inflammation was seen in some 
BeAn-eIFNT mice. These were difficult to score due to variation in level of brain viewed on 
each slide making comparisons difficult. Thus, these data were not included. Overall, 
inflammation was rare in the brains of BeAn-eIFNT mice. The BeAn-eMOPS mice had obvious 
inflammation as well as some demyelination within the pons, brainstem, and cerebellar regions 
of the brain (data not shown). 
 
2.3.3.  Necropsies of Mice Revealed No Abnormalities. 
At termination, the spinal cords and brains were removed and the mouse was placed in a 
50 ml conical tube with fixative at 4°C and necropsies were performed at a later time. No 
animals treated with the capsules demonstrated pathology in any organ systems. Specifically, the 
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organs within the peritoneal cavity were examined for gross pathological changes. The thymus, 
within the chest cavity, was checked as well for signs of atrophy due to lymphopenia. No 
changes were seen in any organ systems. Occasionally, residual capsules were found in the 
peritoneal cavity, but histological examination of tissues revealed no pathological changes due to 
the presence of the capsules (data not shown). 
 
2.4. Discussion 
 The first objective of this investigation was to evaluate treatment efficacy of eIFNT 
during TVID. The eIFNT treatment attenuated the clinical symptoms of TVID. In MS patients, 
IFNB treatment stabilizes the disease (The IFNB Multiple Sclerosis Study Group, 1993), but 
does not result in a decrease in clinical manifestation or a gain of function as was observed in the 
TVID mice during eIFNT treatment. Mice exhibited a decrease in clinical score within two 
weeks of eIFNT treatment and continued to improve over the eight week treatment period. The 
most obvious early indication of treatment efficacy was demonstrated when mice regained their 
normal posture while at rest as well as during ambulation.  Mice had improved coordination as 
well as improved ambulation by the end of the treatment regimen.  A substantial decrease in 
clinical score by 1-2 points within the BeAn-eIFNT-treated group was not expected. It was 
hypothesized that IFNT treatment would cause stabilization in disease. The fact that the animals 
demonstrated a marked clinical improvement is the best verification of treatment efficacy. As 
expected, the BeAn-eMOPS-treated mice showed progressive disability during the eight-week 
treatment period.  
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Figure 7.  Spinal cord sections from BeAn-eIFNT-treated and BeAn-eMOPS-treated mice.  Paraffin 
embedded spinal cords were inspected for inflammation and demyelination using H&E and LFB stains. A) 
H&E stained cervical spinal cord section from a BeAn-eIFNT-treated mouse. There were no indications of 
disease: no inflammation; no demyelination. B) Cervical spinal cord section from the mouse in A stained 
with LFB. No demyelination was present. C) H&E stained cervical spinal cord section from a BeAn-
eMOPS-treated mouse. Note extensive dark bands of inflammation in the meninges (small arrow) as well 
as perivascular cuffing (large arrow) in parenchyma. The pallor in the lateral white matter bordered by 
regions of inflammation indicates demyelination.  D)  LFB stained cervical spinal section from the mouse 
in C. Note the pronounced area of pallor (asterisk) in the lateral white matter as above in C that is 
indicative of demyelination. 
B 
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Figure 8.  Resin-embedded sections of spinal cord from BeAn-eIFNT-treated and BeAn-eMOPS-treated 
mice.  A and B are cervical spinal cord sections from BeAn-eIFNT-treated mice. Both of these sections 
represent a Stage 0=no inflammation or demyelination present. C and D are cervical spinal cord sections 
from BeAn-eMOPS mice. C represents a Stage IV=prominent inflammation and demyelination; moderate 
tissue destruction, multi-focal and prominently extensive in scope, ~ 70% of the area is affected. D 
represents a Stage III=moderate inflammation and demyelination, multi-focal and moderately extensive in 
scope ~30% of the area is affected. 
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Figure 9. Graphical representation of histopathology scores of spinal cords from TVID mice. 
Spinal cord sections from BeAn-eIFNT, BeAn-eMOPS, and PBS-eIFNT mice were scored on 
amount of inflammation/demyelination based on the criteria listed in Section 2.2.11. BeAn-
eMOPS mice had significantly higher histopathology scores (p< 0.05) than BeAn-eIFNT mice. 
BeAn-eMOPS mice had significantly higher scores (p< 0.01) than PBS-eIFNT mice. There was 
no significant difference seen in the histopathological scores between BeAn-eIFNT mice and 
PBS-eIFNT mice. n=12/group. *p<0.05; **p<0.01. 
 
 
 
 
 
 
 
 
 
 34
 Many MS patients (~50%) endure side effects during IFNB treatment and many others 
must stop treatment due to the severity of these side effects (McDonagh et al., 2007). In this 
study, IFNT was well-tolerated and no obvious adverse effects (weight loss, lymphopenia, fever, 
lethargy) were noted during treatment. Likewise, the capsules did not present any negative side 
effects within the mice. None of the mice treated with IFNT-filled or MOPS-filled capsules ever 
suffered adverse effects from the treatment. Necropsies were performed on the mice to evaluate 
internal organs for the presence of pathology as well as the presence of peritonitis. Residual 
beads could be found from time to time, but they did not result in tissue damage, inflammation 
or organ pathology. Thus, the capsules were well-tolerated and the constant release of IFNT did 
not result in mice exhibiting flu-like symptoms of weight loss, fever, and lethargy nor did it 
result in detectable organ pathology. 
 It was surprising that an occasional inflammatory lesion was noted in the meninges of 
eIFNT treated mice without the presence of inflammation within the parenchyma or the presence 
of demyelination. It is suspected that the residual inflammation noted in the CNS of the eIFNT 
mice may be involved in the resolution of the demyelinating lesion and may even influence the 
process of remyelination. The necessity of the immune system during wound healing is well 
documented in the literature. Foote and Blakemore (2005) described the use of inflammation as a 
way to enhance remyelination by transplanted oligodendrocyte progenitor cells (OPCs) in a rat 
model of defective myelination. They found that the advanced meningitis seen in one 
inflammatory model of OPC transplantation resulted in the most widespread remyelination. 
Setzu et al (2006) found the same phenomena when injecting OPCs into the retina for the 
purpose of remyelination. If the site of injection was quiescent, then no remyelination occurred. 
If an inflammatory response was evoked by the injection of an inflammatory compound, then 
remyelination ensued. Thus, it is important that future investigations evaluate the types of cells 
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remaining in the CNS of BeAn-eIFNT-treated mice that have improved clinically in order to 
elucidate the possible role of these cells in CNS repair.  The minimal amount of inflammatory 
cells noted in the brains and spinal cords of some of the eIFNT mice without the presence of any 
demyelinating pathology is supported by the aforementioned studies and it may be that the 
vestigial amounts of inflammation provided an environment conducive to remyelination within 
the eIFNT treated mice. 
 Overall, the treatment efficacy of eIFNT exceeds that seen by IFNB treatment in MS and 
IFNB and IFNT in EAE. In MS patients, disease progression is slowed by 30% during IFNB 
treatment (Tourbah and Lyon-Caen, 2007). In EAE mice, disease development is halted if IFNT 
is administered during the initiation of the disease. However, this effect is dose dependent and 
there is an incidence of disease in some animals at lower (5 x 104) levels of IFNT administration 
(Soos et al., 2002). More recently, investigators have delivered IFNB directly to the CNS with 
genetically engineered bone marrow stem cell (Makar et al., 2008). Even with this direct 
delivery system, the EAE mice had an 80% disease incidence, there was no difference in mean 
clinical score in the acute phase of the disease, and the mice still relapsed. Although the day of 
disease onset was significantly delayed, the duration of the first relapse was shortened, and the 
clinical scores during the relapse and the chronic phases of the disease were lowered, the 
intrathecal expression of IFNB did not improve clinical outcome as did eIFNT in the TVID mice 
in the current study. Like IFNB treatment in MS patients, the IFNB produced in the CNS of EAE 
mice was only able to slow disease progression. IFNB was not able to reverse symptoms nor did 
it result in a gain of function as was shown with eIFNT during TVID within the current study. 
This result is novel in Type I IFN treatment regimens and indicates that IFNT may be providing 
a mechanism that allows lesion resolution and/or encourages remyelination within the CNS. 
Future investigations will evaluate this mechanism using bromo-deoxyuridine to label dividing 
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cells and immunohistochemical markers for oligodendrocyte lineages, myelin, and immune cells 
in order to access the process of lesion resolution and the cells involved in this mechanism 
during eIFNT treatment of TVID. 
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3. CHARACTERIZATION OF CELL-MEDIATED IMMUNE PROFILE 
FOLLOWING IFNT TREATMENT 
 
3.1. Introduction 
It is well accepted that MS is an immune-mediated disease (Trapp and Nave, 2008). 
Although etiology is still unknown, viral infection is suspected as the initiating event that leads to 
autoimmune destruction of myelin (Acheson 1977).  Therefore, in order to understand the 
pathogenesis of MS it is most appropriate to study an animal model of virus-induced 
demyelination such as Theiler's virus infection.  Theiler's murine encephalomyelitis virus 
(TMEV) is a Picornavirus which causes an asymptomatic gastrointestinal infection and 
occasionally paralysis (Theiler, 1934). The BeAn and DA strains of TMEV are avirulent when 
injected i.c.  However, these TMEV strains result in a persistent infection that causes a 
demyelinating disease in certain susceptible strains of mice (SJL) that is similar to MS (Lipton, 
1975). In fact, persistence of TMEV within CNS parenchyma is necessary for the development of 
TVID in susceptible strains of mice (Aubert et al., 1987).  Thus, Theiler's virus infection in mice 
represents not only an excellent model for the study of the pathogenesis of MS but also a model 
system for investigating the mechanisms of action of potential therapeutics in the treatment of 
MS. 
A generally accepted goal of MS treatment is to attenuate a Th1 (pro-inflammatory) 
immune response by shifting to a Th2 (anti-inflammatory) cytokine profile (Baker et al., 1996). 
IFNT has been shown to inhibit Th1 cytokine production in vivo (Newton et al., 1989; Niwano et 
al., 1989; Skopets et al., 1992; Assal-Meliani et al., 1993) and up regulate Th2 cytokines 
(Chaouat et al., 1995).  It is believed that IFNB, a first line treatment for MS, provides disease 
modification by: a) decreasing cell trafficking into the CNS by down-regulating adhesion 
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molecules, such as α4 integrin on brain endothelium, b) decreasing levels of matrix 
metalloproteinases produced by lymphocytes, and c) by causing a shift in the Th1/Th2 immune 
profile (Billiau, et al., 2004). IFNT treatment of EAE resulted in increased IL-10 levels and has 
been proposed to explain the mechanism of action of IFNT (Mujtaba et al., 1997).  The 
importance of IL-10 in EAE has been shown in transgenic mice.  IL-10 deficient mice develop 
more severe EAE and IL-10 over-expressors were completely resistant to disease (Bettelli et al., 
1998). Soos et al. (1997) also found increased levels of IL-10 in IFNT-treated mice and 
increased levels in transforming growth factor beta (TGFB) have also been reported (Khan, et 
al., 1998).  
The objectives for this investigation were to elucidate the cell-mediated responses in 
TVID mice upon exposure to IFNT in vivo. After treatment, mice were terminated and their 
splenocytes were stimulated in vitro with virus in order to evaluate Th1 and Th2 cytokine 
production. Tregs were evaluated in the blood and spleens of animals to quantify any differences 
in the percentage of cells in these two biological compartments. It was hypothesized that Th1 
cyokine production would be reduced for the eIFNT group and that Th2 cytokines would 
increase. Likewise, an increase in the number of Tregs in spleen and/or blood was hypothesized 
within the BeAn-eIFNT-treated mice compared to the BeAn-eMOPS placebo group.  
During TVID and MS, inflammatory cell infiltrates cause damage to self-antigens 
(myelin) within the CNS. CD4+ Treg function is defective in MS patients during a relapse, but the 
function is restored upon remission. Tregs decrease IFN-γ levels secreted by macrophages from 
MS patients (Arnason and Reder, 1994).  Therefore, the TVID model is a valuable tool for testing 
the therapeutic potential of manipulating the Treg population in order to suppress a Th1 response 
as occurs in MS. 
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3.2. Materials and Methods 
3.2.1. Virus Stocks 
 
  The BeAn 8386 strain of TMEV was a gift from Dr. H. L. Lipton (University of Illinois 
at Chicago, IL.)  The virus was propagated in BHK-21 cells, titered, aliquoted, and stored at -80o 
C before use (Welsh et al., 1987). 
 
3.2.2. Animal Infection  
  
 SJL/J mice purchased from Harlan (Indianapolis, IL) were bred in-house. Twenty-eight 
day old female mice were anesthetized with Isoflurane (Vedco, Saint Joseph, MO) and 
inoculated intracranially (i.c.) into the right cerebral hemisphere with 20 µl of  BeAn strain of 
TMEV (5 X 105 plaque forming units) suspended in media or 20 µl of PBS alone. The SJL/J 
mice were divided into two groups as follows: 13 received PBS only and 26 received 5x105 
plaque forming units (pfu) of BeAn virus. The day of i.c. inoculation was considered day 0. All 
animal protocols were in accordance with NIH Guidelines for Care and Use of Laboratory 
Animals and were approved by the Texas A&M University Laboratory Animal Care and Use 
Committee. See Figure 10 for experimental design.  
 
3.2.3. IFNT 
 
IFNT was a gift from Dr. Fuller W. Bazer (Texas A&M Health Science Center, College 
Station, TX). IFNT was isolated as previously described in Ott et al., 1991. The protein 
concentration was determined by the Lowry assay (Lowry et al., 1951) to be 1mg/ml and was 
determined to be 108U/mg by virus plaque assay. 
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3.2.4. IFNT Encapsulation 
 Alginate capsules were prepared as previously described with some modifications 
(Abraham et al., 1996; Arenas-Gamboa et al., 2008). Briefly, 1 ml of 108 U/mg of IFNT was 
mixed with 5 ml of alginate solution (1.5% sodium alginate, 10 mM MOPS, 0.85% NaCl [pH 
7.3]). Spheres were obtained by extruding the suspension through a 200 µm nozzle into a 100 
mM calcium chloride solution and stirred for 15 min by using an Inotech Encapsulator I-50 
(Inotech Biosystems International, Rockville, MD). After extrusion of the IFNT-alginate mixture 
into the CaCl2, the capsules were washed twice with MOPS for 5 min and further cross-linked 
with 0.05% poly-L-lysine (molecular weight. 22,000; Sigma-Aldrich, St. Louis, MO) for 10 min. 
After two successive washes, the beads were stirred in a solution of 0.03% (wt/vol) alginate for 5 
min to apply an outer shell and washed twice with MOPS. VpB was added to the shell of the 
capsule (vjbR::Tn5/VpB/shell) as a cross-linking agent by the addition of VpB in an equimolar 
ratio of poly-L-lysine/VpB. After two successive washes, beads were collected, aliquoted (600 
µl capsules in 900 µl of MOPS buffer) and stored at 4°C.  
Capsules were kept at 4°C in the presence of excess IFNT until time of injection. Before 
injection, capsules were rinsed 3X in MOPS by resuspending capsules and allowing them to 
resettle. Finally, capsules were resuspended in the appropriate amount of MOPS buffer prior to 
injection (900 µl). 
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Figure 10. Experimental design: Section III. The following schematic denotes infection time point (green 
arrow), treatment administration time points (blue arrows), and blood collection time points (red asterisks). 
Time points are in weeks post infection. 
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3.2.5. IFNT Treatment of Mice 
 
Beginning at 11 weeks p.i., a 100 µl i.p. injection of encapsulated IFNT (eIFNT) was 
given every two weeks for a total of eight weeks. An estimated dose of 105 units of IFNT (Soos 
et al., 1995) was released daily from the capsules. Capsules containing MOPS buffer (eMOPS) 
were used as a vehicle control treatment. The groups were as follows: BeAn-infected/eIFNT- 
treated (n=13), BeAn-infected/eMOPS-treated (n=13), and PBS mock-infected/eIFN-treated 
(n=13). 
 
3.2.6. Clinical Scores 
Mice were weighed and evaluated weekly and assigned a clinical score based on disease 
severity. Mice were graded on overall body condition, posture, balance, front and hind limb 
spasticity, and activity level. Clinical scores were based on a scale from 0-6, where 0 indicates a 
healthy animal and 1-6 represent gradually increasing severity of signs as follows: 1:piloerection 
and/or hunched posture with slight gait abnormalities; 2: piloerection and lowered or hunched 
posture plus unsteady gait; 3: very unsteady gait, weak grasp response when placed on wire grid, 
decreased activity level, and occasional slight limb monoparesis; 4: severe hind limb weakness 
and/or spastic paralysis, weight loss, severe decrease in activity level, and loss of the righting 
response; 5: paraparesis of hind limbs and forelimbs, severe weight loss, incontinence, and 
complete loss of righting response; 6:  highly moribund/dead (Borrow et al.,1998).  For these 
observations, animals were examined while walking on a metal grid.  The metal grid allowed 
inspection of an animal's movements from all sides (top, bottom, left and right side) allowing for 
close scrutiny of possible deficits.  There was an inclined area to test an animal's balance and 
strength while ascending or descending. 
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 3.2.7. Single Cell Suspensions from Spleen 
 
Mice were perfused through the left ventricle with heparinized (10 U/ml) Hank’s 
balanced salt solution at pH 7.2. Spleens were removed and placed in RPMI-1640 media on ice. 
Single cell suspensions were prepared as described previously (Welsh et al., 2004).   Briefly, the 
spleens were extruded through nylon mesh attached to a 50 ml beaker. Cells were pelleted by 
centrifugation and resuspended in 2 ml of red blood cell lysis buffer (8.3 g/L ammonium 
chloride in 0.01 M Tris-Cl) and incubated for 2 minutes at room temperature.  Following 
incubation, 10 mls of complete RPMI media was added. Any clot forming in the media was 
removed with a sterile Pasteur pipet prior to centrifugation to prevent cell loss. Cells were rinsed 
by centrifugation. Pellets were resuspended in 10 mls of complete RPMI media and counted with 
a hemacytometer using 0.1% Trypan blue dye. Once counted, cells were pelleted by 
centrifugation and resuspended to a concentration of 2x107 cells/ml.  Fifty microliters of cell 
suspension (per well) were used for ELISpot and in vitro stimulation procedures. 
 
3.2.8. Virus:  Enrichment, UV-Inactivation, and Peptides 
 
The BeAn 8683 strain of TMEV (provided by Dr. H. L. Lipton, University of Illinois at 
Chicago, IL) were propagated in BHK-21 cells as previously described (Welsh et al., 1987). 
Virus was enriched by ultracentrifugation pelleting through a 30% sucrose cushion at 
80,000 x g for 3 hours in an Optima L-80 XP ultracentrifuge (Beckman Coulter) using an SW-28 
rotor (Rueckert and Pallansch, 1981).  Pellets were resuspended in 0.1 M sodium phosphate 
buffer (pH 7.4).  Virus was UV-inactivated by exposing it to UV-light (1330 µW/cm3 at 13 cm 
distance) for 1.5 hours. The immunodominant CD4 T-cell peptide QEAFSHIRIPLPH, 
corresponding to TMEV VP274-86,   was used to determine CD4 T-cell specific responses (Gerety 
et al., 1991 and 1994).  The non-specific peptide sequence RLNRITKDSYPNS (NSP) was used 
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as a control peptide to determine non-specific immune responses.  All peptides were purchased 
from Sigma-Aldrich (St. Louis, MO) at ≥ 95% purity. 
 
3.2.9. In Vitro Stimulation 
For cytokine profiling, 1.0 x 106 splenocytes were cultured with complete RPMI 1640, 
and stimulated with plate bound anti-CD3 (10 µg/ml) and anti-CD28 (2.0 µg/ml), or enriched 
UV-inactivated BeAn, or complete RPMI media  in the presence (5X105U/ml) and absence of 
IFNT for 72 hours at 5.0% CO2 and 37°C.  The supernatants were then collected and stored at -
20°C until analyzed to measure cytokine secretion with Bio-Plex kits (Bio-Rad Laboratories, 
Hercules, CA). 
 
3.2.10. Th1/Th2 Cytokine Profiling 
Th1/Th2 cytokine levels were determined in supernatants from in vitro BeAn-stimulated 
splenocytes using Bio-plex 5-plex luminescence kits according to the manufacturer’s instructions 
(Bio-Rad Laboratories, Hercules, CA).  The following cytokines were quantified: IL-2, IL-10, 
IL-12 (p70), IFNG, and TNFA 
 
3.2.11. T-Regulatory Cell Quantification via Flow Cytometry 
T-regulatory cells were quantified via flow cytometry in the spleens and blood of BeAn-
infected mice treated with eIFNT or eMOPS for eight weeks. Splenocytes were isolated using 
the procedure described in Section 2.11. Upon isolation, splenocytes were diluted to a 
concentration of 1.0 x 106 splenocytes/50 µl and were incubated with 0.5 µg/106 cells of rat anti-
mouse CD16/CD32 (#14-0161; clone 93; eBioscience, San Diego, CA) for 10 minutes on ice to 
block endogenous Fc receptors. Cells were rinsed with flow cytometry staining buffer (#00-
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4222-26; eBioscience, San Diego, CA) and immunostained with the following antibodies from 
eBioscience: FITC conjugated rat anti-mouse CD4 (#11-0042; clone RM4-5), PE-Cy5 
conjugated rat anti-CD45 (#15-0451; clone 30-F11), for 20 minutes at 4°C.  Cells were washed 
3X with flow cytometry staining buffer (eBioscience, San Diego, CA) and resuspended in 1 ml 
of fixation/permeabilization buffer (#72-5775 Foxp3 Kit; eBioscience, San Diego, CA) 
overnight at 4°C. The next day cells were rinsed 3X in permeabilization buffer (#72-5775 Foxp3 
Kit; eBioscience, San Diego, CA) and stained with PE conjugated rat anti-Foxp3 (#72-5775 
Foxp3 kit; clone FJK-16S) 30 minutes at 4°C.   Cells were rinsed 3X in permeabilization buffer 
and then resuspended in 300µl of flow cytometry staining buffer and Treg cell percentages were 
determined using a FACScaliber (Becton Dickson, Franklin Lakes, NJ) and MoFlow software.  
For blood cells, whole blood was collected into 7.5% EDTA. Blood was rinsed 2X with 
centrifugation in PBS + 7.5% EDTA to remove serum and wash blood cells. After the final rinse, 
400 µl of whole blood (suspended in PBS) was blocked with Fc-block as listed above. After 
blocking endogenous Fc receptors, 50 µl of whole blood was stained according to the protocol 
described above for splenocytes.  However, for blood samples, supernatants were removed with 
a Pasteur pipette after each washing step to decrease the number of cells lost by simply decanting 
the solution off of the cells after each wash step. 
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3.3.  Results 
3.3.1. IL-2 Secretion was Slightly Elevated from BeAn-eIFNT-Treated Mouse Splenocytes. 
Cytokine secretion was quantified in the supernatants from splenocytes using Bio-Plex 
5-plex luminescence systems from Bio-Rad. When stimulated in vitro with UV-inactivated 
BeAn (Figure 11A), splenocytes from BeAn-eIFNT mice (76.2±16.79) produced slightly higher 
mean levels of IL-2 than splenocytes from BeAn-eMOPS mice. (60.82±4.20), but the difference 
was not statistically significant. When splenocytes were stimulated with UV-inactivated BeAn in 
the presence of IFNT (Figure 11B), the splenocytes from BeAn-eIFNT-treated mice 
(96.49±13.56) produced more IL-2 than splenocytes from BeAn-eMOPS mice (56.3±3.05).  This 
difference was statistically significant (p< 0.05). Control levels are shown in Figure 13A.  
 
3.3.2. IFNG Secretion was Elevated from BeAn-eIFNT-Treated Mouse Splenocytes.  
Cytokine secretion was quantified in the supernatants from splenocytes using Bio-Plex 
5-plex luminescence systems from Bio-Rad. In response to BeAn stimulation (Figure 12A) in 
vitro, splenocytes from BeAn-eIFNT-treated mice (118±55.21) produced higher mean levels of 
IFNG than did the BeAn-eMOPS mice (15.84±7.83), but the difference was not significant. 
Mean IFNG levels increased further when splenocytes from BeAn-eIFNT-treated mice 
(129.5±70.33) versus those from BeAn-eMOPS mice (24.6±11.54) were stimulated with UV-
inactivated BeAn in the presence of IFNT (Figure 12B) in the culture media, but this difference 
was not significant. Control levels are shown in Figure 13B. 
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Figure  11.  The effect of eIFNT on IL-2 secretion. Splenocytes from BeAn-eIFNT (green squares) mice 
and BeAn-eMOPS (blue circles) mice were stimulated with enriched BeAn for 72 h in the presence or 
absence of IFNT (105U/mg). Supernatants were assayed by Bio-Plex to determine IL-2 production levels. 
A) Splenocytes were stimulated with BeAn alone. The BeAn-eIFNT (green squares) treated mice had 
slightly higher mean levels of IL-2 when compared to BeAn-eMOPS (blue circles) mice, but this 
difference was not significant. B) Splenocytes were stimulated with BeAn in the presence of 105U/mg 
IFNT. The BeAn-eIFNT (green squares) treated mice produced more (p<0.05) IL-2 than the BeAn-
eMOPS (blue circles) mice. The line designates the mean within a group. n=6 mice per group. *p<0.05 
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Figure 12.  The effect of eIFNT on IFNG secretion. Splenocytes from BeAn-eIFNT (green squares) mice and 
BeAneMOPS (blue circles) mice were stimulated with enriched BeAn for 72 h in the presence or absence of IFNT 
(105U/mg). Supernatants were assayed by Bio-Plex to determine IFNG production levels. A) Splenocytes were 
stimulated with BeAn alone. The BeAn-eIFNT (green squares) treated mice had higher mean levels of IFNG when 
compared to BeAn-eMOPS (blue circles) mice, but this difference was not significant. B) Splenocytes stimulated with 
BeAn in the presence of 105U/mg IFNT. Splenocytes from the BeAn-eIFNT (green squares) treated mice produced 
more IFNG than the splenocytes from BeAn-eMOPS (blue circles) mice, but the difference was not significant. The 
line designates the mean within a group. n=6 mice per group. 
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Figure 13. Media and anti-CD3/CD28 controls for IL-2 and IFNG cytokine data. A and B are the negative (media) and 
positive (anti-CD3/CD28) controls for the data in Figures 11 and 12. All data are represented by a diamond shape. 
Actual groups are designated by color as follows: eIFNT-green, eMOPS-blue, and PBS controls-red.  A. Controls for 
IL-2 secretion. B. Controls for IFNG secretion. Lines represent the means for the designated condition.  
 
 50
3.3.3. IL-10 Secretion was Elevated from BeAn-eIFNT-Treated Mouse Splenocytes. 
 Cytokine secretion was quantified in the supernatants from splenocytes using Bio-Plex 
5-plex luminescence systems from Bio-Rad. Splenocytes from BeAn-eIFNT mice (39.75±15.53) 
and BeAn-eMOPS mice (24.41±13.35) secreted low mean amounts of IL-10 when stimulated in 
vitro with UV-inactivated BeAn (Figure 14A). When splenocytes were stimulated with UV-
inactivated BeAn in the presence of IFNT in the culture media (Figure 14B), BeAn-eIFNT mice 
(69.08±26.18) produced higher mean amounts of IL-10 as did the BeAn-eMOPS (33.66±9.26) 
mice, but differences in mean secretion of IL-10 from BeAn-eIFNT mice versus BeAn-eMOPS 
mice were not significant. Control levels are shown in Figure 16A. 
 
3.3.4. TNFA Secretion was Elevated from BeAn-eIFNT-Treated Mouse Splenocytes. 
Cytokine secretion was quantified in the supernatants from splenocytes using Bio-Plex 
5-plex luminescence systems from Bio-Rad. The BeAn-eIFNT treated mice (783.10±336.5) 
produced higher mean levels of TNFA when compared to BeAn-eMOPS (318.40±79.64) mice 
when stimulated with UV-inactivated BeAn (Figure 15A), but this difference was not significant. 
When splenocytes were stimulated with UV-inactivated BeAn in the presence of IFNT (Figure 
15B) in the culture media the BeAn-eIFNT mice (881.90±371.30) produced higher mean levels 
of TNFA when compared to BeAn-eMOPS mice (312.30±98.83), but the differences were not 
significant. Control levels are shown in Figure 16B. 
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Figure 14.   The effect of eIFNT on IL-10 secretion. Splenocytes from BeAn-eIFNT (green squares) mice and BeAn-
eMOPS (blue circles) mice were stimulated with enriched BeAn for 72 h in the presence or absence of IFNT 
(105U/mg). Supernatants were assayed by Bio-Plex to determine IL-10 production levels. A) Splenocytes were 
stimulated with BeAn alone. The BeAn-eIFNT (green squares) treated mice had slightly higher mean levels of IL-10 
when compared to BeAn-eMOPS (blue circles) mice, but this difference was not significant. B) Splenocytes were 
stimulated with BeAn in the presence of 105U/mg IFNT. The BeAn-eIFNT (green squares) treated mice produced 
more IL-10 than the BeAn-eMOPS (blue circles) mice, but the difference was not significant. The line designates the 
mean within a group. n=6 mice per group. 
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Figure 15.  The effect of eIFNT on TNFA secretion. Splenocytes from BeAn-eIFNT (green squares) mice 
and BeAn-eMOPS (blue circles) mice were stimulated with enriched BeAn for 72 hours in the presence or 
absence of IFNT (105U/mg). Supernatants were assayed by Bio-Plex to determine TNFA production 
levels. A) Splenocytes were stimulated with BeAn alone. The BeAn-eIFNT (green squares) treated mice 
demonstrated higher mean levels of TNFA when compared to BeAn-eMOPS (blue circles) mice, but this 
difference failed to reach significance. B) Splenocytes were stimulated with BeAn in the presence of 
105U/mg IFNT. The BeAn-eIFNT (green squares) treated mice produced higher mean levels of TNFA, but 
not significantly higher than the BeAn-eMOPS (blue circles) mice. The line designates the mean within a 
group. n=6 mice per group.  
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Figure 16. Media and anti-CD3/CD28 controls for IL-10 and TNFA cytokine data. A and B are the negative (media) 
and positive (anti-CD3/CD28) controls for the data in Figures 14 and 15. All data are represented by a diamond shape. 
Actual groups are designated by color as follows: eIFNT-green, eMOPS-blue, and PBS controls-red.  A. Controls for 
IL-10 secretion. B. Controls for TNFA secretion.  Lines represent the means for the designated condition.  
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3.3.5. IL-12 (p70) Secretion was Minimal from eIFNT-Treated Mouse Splenocytes.  
Cytokine secretion was quantified in the supernatants from splenocytes using Bio-Plex 5-
plex luminescence systems from Bio-Rad. The BeAn-eIFNT treated (9.84±3.10) and the BeAn-
eMOPS (8.44±0.76) treated mice secreted minimal mean amounts of IL-12 (p70) when 
stimulated in vitro with UV-inactivated BeAn (Figure 17A). Likewise, there was minimal mean 
secretion of IL-12 from BeAn-eIFNT (8.98±3.11) and BeAn-eMOPS (6.73±1.24) treated mouse 
splenocytes when stimulated in vitro with UV-inactivated BeAn in the presence of IFNT (Figure 
17B). No significant difference was seen between the mean levels of IL-12 from BeAn-eIFNT 
and BeAn-eMOPS groups with either culture condition. Control levels are shown in Figure 18. 
 
3.3.6. Percentages of T-Regulatory Cells were Not Affected by IFNT Treatment. 
Flow cytometry of the percentage of CD4+CD45+Foxp3+ T-cells in the spleen (Figure 
19A) revealed high percentages in both BeAn-eIFNT (4.23±0.31) and BeAn-eMOPS 
(4.25±0.40) treated mice and these percentages were similar to those seen in PBS (4.17±0.22) 
control mice treated with eIFNT. The percentages of CD4+CD45+Foxp3+ T-cells in the blood 
(Figure 19B) were much lower than in the spleens in all three groups. No significance difference 
in percentages of Foxp3+ cells in the blood was seen between the BeAn-eIFNT (0.9±0.26), 
BeAn-eMOPS (1.07±0.19) or PBS-eIFNT (1.37±0.18) groups. 
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Figure  17.  The effect of eIFNT on IL-12(p70) secretion. Splenocytes from BeAn-eIFNT (green squares) 
mice and BeAn-eMOPS (blue circles) mice were stimulated with UV-inactivated, enriched BeAn for 72 
hours in the presence or absence of IFNT (105U/mg). Supernatants were assayed by Bio-Plex to determine 
IL-12(p70) production levels. A) Splenocytes were stimulated with BeAn alone. The BeAn-eIFNT (green 
squares) treated and the BeAn-eMOPS (blue circles) treated mice secreted minimal mean amounts of IL-
12 (p70) B) Splenocytes were stimulated with BeAn in the presence of 105U/mg IFNT. The BeAn-eIFNT 
(green squares) treated mice and the BeAn-eMOPS (blue circles) treated mice produced minimal mean 
amounts of IL-12(p70). The presence of IFNT in the culture system caused no difference in the level of 
IL-12(p70) secretion within either group. The line designates the mean within a group. n=6 mice per 
group. 
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Figure 18. Media and anti-CD3/CD28 controls for IL-12 (p70) cytokine data. This graph shows the negative (media) 
and positive (anti-CD3/CD28) controls for the data in Figure 17. All data are represented by a diamond shape. Actual 
groups are designated by color as follows: eIFNT-green, eMOPS-blue, and PBS controls-red.  Lines represent the 
means for the designated condition.  
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Figure 19. The effect of eIFNT treatment on percentage of Foxp3 cells in spleen and blood. Percentages of 
CD4+CD45+Foxp3+ T cells were enumerated in spleen and blood by flow cytometry. A) The spleen had a 
high percentage of Foxp3+ T cells. There were no differences seen between the eIFNT (green squares) and 
eMOPS (blue circles) groups. B) The percentages of Foxp3+ T cells in the blood were much lower than in 
the spleens in both groups. No significance difference was seen between the eIFNT (green squares) and 
eMOPS (blue squares) groups. Lines represent means for each group. n=7 -8 mice per group. 
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3.4. Discussion 
The hypothesis tested in this investigation was that eIFNT mediated its therapeutic effect 
by shifting a Th1 immune profile to a Th2 immune profile. However, an obvious shift was not 
demonstrated. In fact, there were no elevated levels of Il-4, IL-5, or IL-6 noted during in vitro 
stimulation of BeAn-specific splenocytes.  
The only cytokine to demonstrate statistical significance between BeAn-eIFNT-treated 
mice and BeAn-eMOPS mice was IL-2. When stimulated with UV-inactivated BeAn alone 
(Figure 11A), the splenocytes from Bean-eIFNT mice showed a very slight increase over the 
BeAn-eMOPS splenocytes (76.2 ± 16.79 pg/ml vs. 60.82 ± 4.20 pg/ml). When IFNT (Figure 
11B) was added to the culture system during UV-inactivated BeAn stimulation, the mean 
amount of IL-2 produced by the splenocytes of BeAn-eIFNT mice was statistically increased 
from the mean amount secreted by BeAn-eMOPS splenocytes (96.49 ± 13.56 pg/ml versus 56.3 
± 3.05 pg/ml). IL-2 is required as a growth factor and a survival factor for Th1 T-cells. It is also 
a survival factor for Treg cells.  Thus, its presence is to be expected during the stimulation with 
BeAn antigen in the culture condition used in this study. Although there was an increase of IL-2 
production by splenocytes from the eIFNT mice when cultured in the presence of IFNT, the 
levels of production were not dramatic and it is not known if the IL-2 was from Th1 cells or Treg 
cells. It is also unclear which cell type may be using the cytokine for survival since mixed 
splenocyte cultures were used.  The increase in IL-2 produced by IFNT mice may reflect 
increased populations of T-regulatory cells since iTregs are antigen-dependent like effector Th1 
cells. This could provide a mechanism of disease modification if the increase in IL-2 reflects the 
presence and activity of Tregs rather than Th1 effector cells. An increased number of Tregs has 
been noted in MS patients after IFNB treatment (Venken et al., 2007).  Future investigations will 
entail the use of a Miltenyi Magnetic Cell Sorting system to purify cell populations in order to 
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more clearly define cell source of cytokine. However, as demonstrated in Figures 19A and 19B, 
differences in Treg cell percentages do not appear to be a possible mechanism of disease 
modulation within the experimental conditions employed. However, their activation status may 
warrant further investigation. 
Mean IFNG production by BeAn-eIFNT splenocytes was highly elevated compared to 
production by BeAn-eMOPs splenocytes when stimulated by UV-inactivated BeAn alone (118 ± 
55.21 pg/ml versus 15.84 ± 7.83 pg/ml) or in the presence of IFNT (129.5 ± 70.33 pg/ml versus 
24.6±11.54 pg/ml) in the culture media (Figures 12A and 12B). IFNG is produced by Th1 cells 
and is considered the hallmark cytokine of a Th1 type immune response. Thus, the increased 
production of IFNG by splenocytes from BeAn-eIFNT mice was unexpected as it suggests an 
up-regulation of the Th1 immune profile which refutes the stated hypothesis of this study. 
However, this increased production of IFNG from BeAn-eIFNT mice was not significant due to 
a broad range of secretion from the splenocytes of BeAn-IFNT mice. This broad range in 
secretion causes a large SEM and results in a non-significant difference between the BeAn-
eIFNT and BeAn-eMOPS groups. However, the wide range of response does not appear to 
reflect outliers in the data set. The distribution pattern as seen in the scatter plot (Figures 12A 
and 12B) is more indicative of the presence of biological responders and non-responders within 
the eIFNT group. This situation is seen by other researchers and is a common obstacle when 
investigating Type I IFN disease modifying drugs and reporting biological measures that reflect 
treatment efficacy. However, all BeAn-eIFNT mice included in the present studies demonstrated 
improvement in clinical score indicating that all of the mice were biological responders to the 
eIFNT treatment. Thus, the explanation for the differences between mice that produce high 
levels of IFNG in response to IFNT stimulation and those that produce low levels of IFNG in 
response to IFNT stimulation remains elusive at this time. However, this difference suggests that 
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individuals may respond differently to a disease modifying drug, but still exhibit disease 
attenuation. It is possible that the increased production of IFNG is required for the induction of 
apoptosis in pathologic T-cells through the activation induced cell death pathway (AICD) 
suggested by other researchers (Refaeli et al., 2002). It is proposed that IFNG stimulates this 
effect through the activation of Stat1 and its stimulation of caspases. This alternative would 
decrease the number of pathologic Th1 cells in the periphery, thus, excluding them from the pool 
that is available to traffic to the CNS and contribute to demyelinating pathology. Another 
explanation is that the IFNG is being enlisted as an anti-viral agent and is lowering the viral load 
which would lower immune responses to the virus and should be reflected in a decrease in 
disease activity. SJL/J mice treated with antibodies to IFNG suffered an increase in 
demyelination (Rodriguez et al., 1995).  In addition, IFNG knock-out mice on a TVID resistant 
background suffered increased demyelination and mortality when infected with Theiler's virus 
(Fiette et al., 1995). These studies suggest the importance of IFNG in the resistance to TVID.  At 
this time, the discrepancy in amount of IFNG produced by BeAn-eIFNT mice does not reflect a 
lack of response to the IFNT as seen in the eMOPS group since all of the eIFNT mice showed 
clinical improvement.  The splenocytes from BeAn-eMOPS mice did not exhibit a dramatic 
increase in IFNG production upon exposure to IFNT in vitro.  This suggests that the splenocytes 
from the Bean-eIFNT group are biologically different from those found in the BeAn-eMOPS 
group. Future studies into the intracellular signaling pathways induced by IFNT stimulation by 
the high and low IFNG-secreting splenocytes should elucidate the cell machinery producing the 
variable responses and may provide information for future treatment targets. 
Mean IL-10 production (Figure 14A) by BeAn-eIFNT splenocytes was slightly elevated 
over BeAn-eMOPS (39.75 ± 15.53 pg/ml versus 24.41 ± 13.35 pg/ml) splenocytes during in 
vitro stimulation with UV-inactivated BeAn virus. There was an even larger increase in mean 
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IL-10 production from the eIFNT splenocytes versus the eMOPS splenocytes when IFNT Figure 
14B) was added to the culture system (69.08 ± 26.18 pg/ml versus 33.66 ± 9.26 pg/ml). Once 
again, this increase was not significant due to a wide range of responses from the eIFNT group. 
However, all mice responded to in vivo IFNT with a decrease in clinical score and are considered 
biological responders to the Type I IFN treatment regimen. IL-10 is one of the cytokines 
considered as anti-inflammatory. It is the counterpart of IL-12, the cytokine responsible for 
polarizing T-cells toward a Th1 profile. Thus, an increase in IL-10 was hypothesized for this 
study as a mechanism of IFNT immune modulation. In fact, an increase in IL-10 is considered 
one of the most reliable measures of biologic response to Type I IFN treatment in MS patients 
(Kumpfel et al., 2000; Kumpfel et al., 2007). However, the discrepancy in splenocyte response 
from the eIFNT group is a paradox to the decrease in disease severity witnessed in all of the 
Type I IFN- treated mice.   
 The most notable change in level of cytokine production was for TNFA. Mean TNFA 
production was increased dramatically from BeAn-eIFNT splenocytes (Figures 15A and 15B) 
and the levels were highly elevated compared to the levels produced by BeAn-eMOPS 
splenocytes in response to UV-inactivated BeAn stimulation alone (783.10 ± 336.5 pg/ml versus 
318.40±79.64 pg/ml) and in the presence of IFNT (881.90 ± 371.30 pg/ml versus 312.30 ± 98.83 
pg/ml).  Similar to results from measurements of other cytokines, the levels produced by the 
eIFNT splenocytes demonstrated a wide range which resulted in a large SEM and a lack of 
statistical significance. However, all mice did respond to in vivo IFNT treatment with a decrease 
in disease activity. Such high levels of TNFA were unexpected as it is considered a pro-
inflammatory cytokine and does not fit the clinical picture observed in the eIFNT mice. In fact, 
high levels of TNFA have been detected in the spinal cords of TMEV-infected SJL mice and 
disease was suppressed by treatment with monoclonal antibody to TNFA (Inoue et al., 1996). In 
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another study, administration of TNFA (Paya et al., 1990) to TVID susceptible mice resulted in 
reduced demyelination. Such high levels of in vitro TNFA production are similar to the results of 
our laboratory (Welsh et al, 1995) where high levels of TNFA have been shown to inhibit TVEV 
replication in cultured CVE cells. Likewise, its role in this study appears to be beneficial and 
result in disease modification, possibly through anti-viral effects. 
The least notable mean level of cytokine production was seen for IL-12 (Figures 17A 
and 17B). The production of IL-12 from both the BeAn-eIFNT and BeAn-eMOPS splenocytes 
were at levels barely detectable with the Bio-Plex assay system whether stimulated with UV-
inactivated BeAn alone (9.84 ± 3.10 pg/ml versus 8.44±0.76 pg/ml) or in the presence of IFNT 
(8.98 ± 3.11 pg/ml or 6.73 ± 1.24 pg/ml). These production levels are expected in the current 
culture conditions because T-cells do not produce IL-12 in response to antigen stimulation, as 
APCs, such as macrophages, produce IL-12. Since the BeAn was UV-inactivated, the APCs 
resident within the splenocyte population should not respond to the virus with activation and pro-
inflammatory cytokine secretion. Thus, this measurement is more of an indication that the 
culture system utilized an antigen-specific condition and that other cytokines produced were 
antigen dependent in nature. However, it should be noted that even this cytokine revealed two 
populations of responders as noted by the scatter plot (Figures 17A and 17B) suggesting that 
even APCs from eIFNT treated mice exhibit a biological difference in response to Type I IFN 
treatment. 
An additional test of the culture system’s antigen-specific dependence is presented in 
Figures 13A, 13B, 16A, 16B and 18. The results presented in these figures are the medium 
controls (negative control) and the anti-CD3/CD28-stimulated positive controls. BeAn-eIFNT 
and BeAn-eMOPS splenocytes were assessed in negative and positive control conditions in order 
to evaluate response specificity. The anti-CD3/CD28 condition cross-links the T-cell receptor 
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and yields optimal antigen-independent activation. Thus, the anti-CD3/CD28 condition usually 
manifests the highest amount of cytokine production. The media (negative) control condition 
provides the amount of cytokines produced constitutively in the culture system. The levels of 
cytokines produced in all negative and positive controls supported the specificity of cytokines 
produced in the presence of UV-inactivated BeAn. An interesting observation is that the mice 
that responded with the highest production levels did so for all cytokines evaluated (IL-2, IFNG, 
TNFA and IL-10). However, these same mice did not produce the highest levels of cytokines 
during the anti-CD3/CD28 condition. This finding implies that the splenocytes that respond with 
high cytokine production are not just hyper-responsive cells. Their increased cytokine production 
is an actual manifestation of a biological difference in response within the splenocytes of mice 
primed in vivo with eIFNT. The “low responders” in the BeAn-eIFNT group easily produce high 
levels of cytokines in the anti-CD3/CD28 condition. Thus, their decreased cytokine production is 
not an indication of an inability to respond robustly to activation.  
Overall, the cytokine findings warrant further investigations that: a) utilize purified cell 
cultures to better identify which cell type is producing each cytokine in response to antigen 
stimulation; b) examine intracellular signaling pathways to establish a difference between the 
high and low responses in cytokine production observed in these studies; and c) employ 
molecular techniques, such as microarray technology, to pinpoint genomic differences in relation 
to biological response. 
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4.  CHARACTERIZATION OF HUMORAL IMMUNE PROFILE 
FOLLOWING IFNT TREATMENT 
 
4.1. Introduction 
MS is a chronic inflammatory demyelinating disease of the CNS. The etiology of MS 
remains elusive, yet viral infection is suspected. The presence of oligoclonal bands within the 
CNS of MS patients is considered one of the diagnostic criteria for this disease. However, the 
amount of research dedicated to this facet of the disease is sparse. Recently, this area has become 
more popular due to the observations of Serafini et al., 2007. These researchers noted the 
presence of Epstein-Barr Virus (EBV) positive B cells within the parenchyma of the majority of 
MS patients. These same researchers (Serafini et al., 2004) and others (Aloisi and Pujol-Borrell, 
2006) have now described the presence of germinal centers like those seen in peripheral lymph 
nodes within the meninges of MS patients. Finally, the recent use of rituximab as a successful 
treatment in MS patients has shown that B-cell depletion is a potential disease modifying 
mechanism (Hauser, 2008). These results suggest that antibody production during MS is crucial 
to the disease mechanism and warrant further investigation. 
The proposed mechanism of disease modifying drugs in MS is through a shift in a 
Th1/Th2 immune profile. If this is true, and MS pathology has a humoral component, then a shift 
to a more aggressive antibody response may result in disease exacerbation. If this simplistic view 
is correct, then a Th2 shift is not necessarily a desired goal of treatment regimens. In fact, the 
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most beneficial treatment would modulate then entire immune system and result in a quieting of 
the immune response and a switch to wound healing mechanisms. In this scenario, wound 
healing would entail the replacement of lost/damaged myelin. However, if MS has a viral 
etiology, then an increase in antibody production could be utilized to clear disease-initiating 
virus within the MS patient’s CNS and decrease disease activity. 
The purpose of the current study was to investigate the effect of eIFNT on the humoral 
response to TMEV. More specifically, sera from BeAn-infected mice treated with eIFNT and 
eMOPS were evaluated for virus-specific antibodies. It was hypothesized that: a) serum antibody 
levels specific for TMEV would increase; and b) ELISPot assays would detect an increase in 
virus-specific antibody secreting cells (ASCs) within the spleens and CNS of treated mice, 
supporting a switch in immune profile from a Th1 response to a Th2 response.  It was predicted 
that increases in virus-specific antibodies and virus-specific ASCs would allow the SJL mice to 
finally clear the persistent TMEV infection within their CNS and that this outcome would 
decrease the severity of this demyelinating disease. 
 
 
 
 
 
 
 
 
 
 
 66
4.2. Materials and Methods 
4.2.1. Virus Stocks 
 
  The BeAn strain of TMEV was a gift from Dr. H. L. Lipton (Northwestern University, 
Evanston, IL.)  The virus was propagated in BHK-21 cells, titered, aliquoted, and stored at -80o 
C before use (Welsh et al., 1987). 
 
4.2.2. Animal Infection  
  
 SJL/J breeder mice were purchased from Harlan (Indianapolis, IL) and the mice used in 
this project were bred in-house. Twenty-eight day old female mice were anesthetized with 
Isoflurane (Vedco, Saint Joseph, MO) and inoculated intracranially (i.c.) into the right cerebral 
hemisphere with 20 µl of  BeAn strain of TMEV (5 X 105 plaque forming units) suspended in 
media or 20 µl of PBS alone. The SJL/J mice were divided into two groups as follows: 18 
received PBS only and 36 received 5x105 plaque forming units (pfu) of BeAn virus. The day of 
i.c. infection was considered day 0. See Figure 20 for experimental design. 
 
4.2.3. IFNT 
 
IFNT was a gift from Dr. Fuller W. Bazer (Texas A&M University, College Station, 
TX). IFNT was isolated as previously described in Ott et al., 1991. The protein concentration 
was determined to be 1mg/ml by Lowry assay (Lowry et al., 1951) and 108U/mg by virus plaque 
assay. 
 
4.2.4. IFNT Encapsulation 
 Alginate capsules were prepared as previously described with some modifications 
(Abraham et al., 1996; Arenas-Gamboa et al., 2008). Briefly, 1 ml of 108 U/mg of IFNT was 
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mixed with 5 ml of alginate solution (1.5% sodium alginate, 10 mM MOPS, 0.85% NaCl [pH 
7.3]). Capsules were obtained by extruding the suspension through a 200 µm nozzle into a 100 
mM calcium chloride solution and stirred for 15 min by using an Inotech Encapsulator I-50 
(Inotech Biosystems International, Rockville, MD). After extrusion of the IFNT-alginate mixture 
into the CaCl2, the capsules were washed twice with MOPS for 5 min and further cross-linked 
with 0.05% poly-L-lysine (molecular weight. 22,000; Sigma-Aldrich, St. Louis, MO) for 10 min. 
After two successive washes, the beads were stirred in a solution of 0.03% (wt/vol) alginate for 5 
min to apply an outer shell and washed twice with MOPS. VpB was added to the shell of the 
capsule (vjbR::Tn5/VpB/shell) as a cross-linking agent by the addition of VpB in an equimolar 
ratio of poly-L-lysine/VpB. After two successive washes, beads were collected, aliquoted (600 
µl capsules in 900 µl of MOPS buffer) and stored at 4°C.  
Capsules were kept at 4°C in the presence of excess IFNT until time of injection. Before 
injection, capsules were rinsed 3X in MOPS by resuspending capsules and allowing them to 
resettle. Finally, capsules were resuspended in the appropriate amount of MOPS buffer prior to 
injection (900 µl). 
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Figure 20. Experimental design: Section IV. The following schematic denotes infection time point (green 
arrow), treatment administration time points (blue arrows), and blood collection time points (red asterisks). 
Time points are in weeks post-infection 
 
 
 
 
 
 
 
 
 
 
 
 
II nn
ff ee
cc tt
ii oo
nn   
T
er
m
in
at
io
n 
   
T
re
at
m
en
t 1
 
   
T
re
at
m
en
t 2
 
   
T
re
at
m
en
t 3
 
   
T
re
at
m
en
t 4
 
 
 » » » 
» Blood
11
 W
ee
ks
  
T
im
e 
0 
  
20
 W
ee
ks
  
 69
4.2.5. IFNT Treatment of Mice 
 
Beginning at 11 weeks p.i., a 100µl i.p. injection of encapsulated IFNT (eIFNT) was 
given every two weeks for a total of eight weeks. A dose of 105 units of IFNT (Soos et al., 1995) 
was released daily from the capsules. Capsules containing MOPS buffer (eMOPS) were used as 
a vehicle control treatment. The groups were as follows: BeAn infected/eIFNT treated (n=13), 
BeAn infected/ eMOPS treated (n=13), and PBS mock infected/eIFN treated (n=13). 
 
4.2.6. Clinical Scores 
 
Mice were weighed and evaluated weekly and assigned a clinical score based on disease 
severity. Mice were graded on overall body condition, posture, balance, front and hind limb 
spasticity, and activity level. Clinical scores were based on a scale from 0-6, where 0 indicates a 
healthy animal and 1-6 represent gradually increasing severity of signs as follows: 1:piloerection 
and/or hunched posture with slight gait abnormalities; 2: piloerection and lowered or hunched 
posture plus unsteady gait; 3: very unsteady gait, weak grasp response when placed on wire grid, 
decreased activity level, and occasional slight limb monoparesis; 4: severe hind limb weakness 
and/or spastic paralysis, weight loss, severe decrease in activity level, and loss of the righting 
response; 5: paraparesis of hind limbs and forelimbs, severe weight loss, incontinence, and 
complete loss of righting response; 6: highly moribund/dead (Borrow, et al.,1998).  For these 
observations, animals were examined while walking on a metal grid.  The metal grid permitted 
inspection of an animal's movements from all sides (top, bottom, left and right side) allowing for 
close scrutiny of possible deficits.  An inclined area was used to test an animal's balance and 
strength while ascending or descending. 
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4.2.7. Blood Collection 
Blood samples were obtained from the tail vein of mice three times during the course of 
the experiment to determine TMEV-specific antibody titers. The mice were bled prior to 
infection (baseline), at 11 weeks post-infection, and at necropsy.   The blood was collected in 1.5 
ml microfuge tubes and placed on ice.   Blood was allowed to clot for 24 h at 4°C. The clotted 
samples were centrifuged at 3000rpm for 10 min. Sera was collected and stored at -20°C until 
analyzed with ELISA. 
 
4.2.8. Single Cell Suspensions from Spleen, Brain, and Spinal Cord Isolation 
 
Mice were perfused through the left ventricle with heparinized (10 U/ml) Hank’s 
balanced salts solution at pH 7.2. Brains, spinal cords, and spleens were removed and placed in 
complete RPMI-1640 (1.0% L-glutamine, 1.0% penicillin/streptomycin and 10% FBS) media on 
ice. Single cell suspensions were prepared from spleens as described previously (Welsh et al., 
2004).   CNS infiltrating lymphocytes (CNS-ILs) were prepared from brains (Br-ILs) and spinal 
cords (SC-ILs). CNS tissues were extruded through nylon mesh attached to a 50ml beaker using 
the plunger of a 5ml syringe. Tissue was pelleted by centrifugation and the pellet was 
resuspended in 2 mls of 250µg/ml of Collagenase IV (Worthington Inc., Lakewood, NJ) in 
RPMI-1640 with 2% FBS for 45 minutes at  37°C and 5% CO2.  Tissues were agitated every 15 
min to enhance collagenase digestion. Following incubation, the digested tissues were rinsed in 
complete RPMI media by centrifugation. Lymphocytes were isolated by 35%/70% percoll 
gradient centrifugation (Irani and Griffin, 1991), resuspended in complete RPMI-1640 to the 
desired concentration, and placed on ice until needed. 
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4.2.9. Virus:  Enrichment and UV- Inactivation 
 
The GDVII and BeAn strains of TMEV (provided by Dr. H. L. Lipton, University of 
Illinois at Chicago, IL) were propagated in BHK-21 cells (Welsh et al., 1987). 
Virus was enriched by ultracentrifugation pelleting through a 30% sucrose cushion at 
80,000 x g for 3 h in an Optima L-80 XP ultracentrifuge (Beckman Coulter) using an SW-28 
rotor (Rueckert and Pallansch, 1981).  Virus pellets were resuspended in 0.1M sodium phosphate 
buffer (pH 7.4).  Virus was assayed for total protein concentration with Bio-Rad Protein Assay 
reagent. Viral purity was confirmed by SDS-PAGE (Figure 21). Finally, virus was UV-
inactivated by exposing it to UV-light (1330 µW/cm3 at 13 cm distance) for 1.5 h.    
 
4.2.10. Serum Antibodies to TMEV 
Serum antibody titers against TMEV were analyzed by ELISA.  Briefly, enriched UV-
inactivated GDVII virus was used to coat 96-well plates (Costar #3590) at a concentration of 
0.25 µg/100 µl/well in carbonate buffer for 24 h at 4°C.  Plates were rinsed 3 X with assay buffer 
and once with RO–H2O.  Plates were blocked by applying 100 µl SuperBlock buffer (#37515; 
Pierce) followed by immediate removal and replacement of blocking buffer for a total of three 
times according to manufacturer’s instructions. Serum samples were diluted in assay buffer 
starting at 1/100 and serially diluted to 1/6400. Assay buffer served as the background control. 
Plates were incubated for 90 min at room temperature. Plates were washed 3X with assay buffer 
and once with RO–H2O. HRP-conjugated goat anti-mouse polyvalent immunoglobulin (#A0412; 
Sigma-Aldrich, St. Louis, MO) was diluted 1/500 in assay buffer and plates incubated for 60 min 
at room temperature.  Plates were rinsed 3X with assay buffer and once with RO-H2O. The 
reaction was developed with 100 µl of OPD substrate (#P9187; Sigma-Aldrich, St. Louis, MO) 
for 10 min according to the manufacturer’s instructions. The reaction was quenched with 50 µl 
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Figure 21.  Enriched GDVII visualized by SDS-PAGE. The GDVII strain of TMEV was enriched by 
ultracentrifugation through a sucrose cushion. The gel image shown above represents three enriched virus 
samples diluted 1:6 in loading buffer. For each sample, 5 µl and 10 µl aliquots were loaded. The bands are 
identified as follows on the gel: BSA (69kD), VP0 (35kD), VP1 and VP2 (~32kD) and VP3 (20kD). The 
combined protein concentration of this virus enrichment was 382 µg/ml of pure virus (510 µg/ml of total 
protein). The BeAn strain of TMEV was enriched, assayed for protein concentration, and visualized by 
SDS-PAGE as seen above for the GDVII strain of TMEV. BSA=bovine serum albumin, VP=viral peptide, 
MM=molecular marker 
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of 2.0M sulfuric acid.  Optical density was read at 490nm using a FLUOstar Optima 
spectrophotometer (BMG Inc., Offenburg, Germany). Background was subtracted from each 
column. 
 
4.2.11. ELISpot Assay 
 
Virus-specific antibody producing cells (APCs) were determined using an ELISpot 
assay.  For this assay, 96-well PVDF membrane filtration plates (MAIPS4510; Millipore, Corp, 
Bedford, MA) were coated with 1.0µg/well of enriched GDVII strain of TMEV virus in 100 µl 
sterile PBS and incubated overnight  at 4°C.  The plates were blocked with 200µl RPMI-1640 + 
10% FBS for 2 h at room temperature.  After blocking, either 2.0 x 104 Br-ILs or SC-ILs or 1.0 x 
106 splenocytes were added to each well.  Samples were run in duplicate. The plate was 
incubated at 37° C and 5.0% CO2 for 24 h.  The plates were washed gently 6X with PBS 
containing 0.05% Tween-20 to preserve membrane integrity, but remove cells. Plates were 
rinsed once with water purified by reverse osmosis (RO- H2O).   Biotinylated goat anti-mouse 
IgG + IgM (#115-065-044, Jackson Laboratories, Bar Harbor, ME) was added at 1:500 as 
described (Pachner et al., 2007) and incubated for 2 h at room temperature.  After incubation, 
plates were washed 6X with PBS containing 0.05% Tween-20.  Then, 100 µl of avidin-HRP 
(horseradish peroxidase; #18-4100-51; eBioscience) diluted 1/1000 in assay diluent was added to 
each well and the plates incubated for 30 min at room temperature.  After washing 6X with PBS 
+ 0.05% Tween-20, spots were developed using 100 µl of 3-amino-9-ethyl-carbazole (AEC) 
substrate solution (1.0 mg AEC, 1.0 ml dimethylformamide, 14 ml 0.1M citrate-phosphate buffer 
pH 5.0, and 10.0 µl and H2O2).  After development, the plates were rinsed 3X with 200 µl of 
RO-H2O, and read with an ELISpot plate reader (AID ELISpot Reader System, Straberg, 
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Germany).   Background was determined as the number of spots generated to RPMI-1640 media 
and this value was subtracted from each well of virus-specific antibody responses.   
 
4.3. Results 
 
4.3.1. No Differences were Seen in Number of Virus-Specific Antibody Secreting Cells in 
Spleens of Bean-eIFNT and Bean-eMOPS Mice. 
 
Splenocytes from BeAn-eIFNT and BeAn-eMOPS treated mice were plated on UV-
inactivated BeAn-coated membrane filtration plates for 24 h at which time cells were rinsed 
from the membranes and the plates were developed as ELISPots. The number of ASCs from the 
spleens (Figure 22) of BeAn-eIFNT mice were slightly lower (15.07±2.74) than the ASCs from 
the BeAn-eMOPS mice (19.50±2.82), but the difference was not significant. As expected, PBS 
control mice showed very low numbers of virus-specific ASCs (2.38±0.74). 
 
4.3.2. Virus-Specific Antibody Secreting Cells in the Brains of BeAn-eIFNT Mice. 
 Br-ILs were isolated and plated on UV-inactivated BeAn-coated membrane filtration 
plates for 24 hours at which time cells were rinsed from the membranes and the plates were 
developed as ELISPots.  The ELISpot assay quantifies the number of cells specific for the 
antigen utilized in the system. For these results (Figure 23A), the number of brain-isolated virus-
specific ASCs were slightly lower in the BeAn-eIFNT mice (3.29±1.01) when compared to 
Bean-eMOPS mice (7.75±1.70), but this difference was not statistically significant. The PBS 
control mice (0.83±0.60) barely had detectable numbers of ASCs isolated from their brain 
parenchyma. 
 
 
 75
BeAn-eINF BeAn-eMOPS PBS-eINF
0
10
2
0
3
0
4
0
5
0
5
5
7
0
N
u
m
b
e
r 
o
f 
 T
M
E
V
-s
p
e
ci
fi
c 
C
e
ll
s
  
Figure 22.  The effect of eIFNT on BeAn-specific antibody secreting cells in the spleen. Splenocytes were 
cultured for 24 hours in UV-inactivated GDVII coated membrane filtration plates. Cells were rinsed off 
and the plates were developed as ELISPots and read on an AID ELISpot Reader.  The BeAn-eIFNT 
splenocytes (green squares) produced slightly lower mean numbers of virus-specific antibody producing 
cells (ASC) compared to BeAn-eMOPS splenocytes (blue circles). The difference was not statistically 
significant.  PBS mice showed very few ASC. Lines represent means of each group. n=14 for BeAn-
eIFNT and BeAn-eMOPS groups; n=8 for PBS group. 
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4.3.3. Virus-Specific Antibody Secreting Cells in the Spinal Cords of BeAn-eIFNT Mice. 
SC-ILs were isolated and plated on UV-inactivated BeAn-coated membrane filtration 
plates for 24 hours at which time cells were rinsed from the membranes and the plates were 
developed as ELISPots. The ELISpot assay quantifies the number of cells specific for the 
antigen used in the system. For these results (Figure 23B), spinal cord-isolated virus-specific 
ASCs revealed slightly higher means in the BeAn-eIFNT mice (8.5±2.4) than from the BeAn-
eMOPS mice (3.81±2.03). This difference was not significant. The PBS control mice 
(2.67±0.73) had numbers of virus-specific ASCs similar to those of BeAn-eMOPS mice. 
 
4.3.4. Virus-Specific Serum Antibody Levels after eIFNT Treatment. 
Mice were bled before treatment began (pre-treatment bleed) and at termination (post-
treatment bleed). Sera from mice were used to quantify virus-specific antibody levels with a 
GDVII ELISA. Data are presented (Figure 24) as average OD readings from 12 mice per group 
whose sera was diluted from 1/100 to 1/6400.  Mean pre-treatment OD values for virus-specific 
serum antibodies from Bean-eIFNT and Bean-eMOPS were similar at 1/200 dilutions (1.20±0.14 
versus 1.47±0.13). At post-treatment, the mean OD values at the 1/200 dilution were lower in the 
Bean-eIFNT mice (0.99±0.22) compared to the BeAn-eMOPS mice (1.74±0.14). None of these 
differences were significant. As expected, the PBS control mice did not show OD readings above 
baseline.  
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Figure 23.  The effect of eIFNT on BeAn-specific ASCs in the CNS. Splenocytes were cultured for 24 h in 
UV-inactivated GDVII coated membrane filtration plates. Cells were rinsed off and the plates were 
developed as ELIPots and read on an AID ELISpot Reader.  A) The number of virus-specific ASCs in the 
Br-ILs isolated from TVID mice treated with eIFNT (green squares) were lower than those from eMOPS 
(blue circles) treated mice. This difference is not statistically significant. The number of brain-derived 
ASCs in PBS control mice was very low.   B) The number of virus-specific ASCs in the SC-ILs isolated 
from TVID mice treated with eIFNT (green squares) was higher than those from BeAn-eMOPS mice, but 
the difference was not significant. The number of virus-specific ASCs in the spinal cords of PBS control 
mice was very low. The lines represent the means of each group. n=8 for the eIFNT and eMOPS groups. 
n=3 for PBS control mice. Br-ILS=brain infiltrating lymphocytes, SC-ILs=spinal cord infiltrating 
lymphocytes 
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Figure 24.  Effect of eIFNT on TMEV-specific serum antibodies. Mice were bled before treatment started 
(pre-treatment) and upon termination (post-treatment) of the experiment.  Serum antibodies were tested 
using enriched GDVII in an ELISA system. OD readings reflect amount of antibody present to virus 
within the sera. The mean 1/200 readings are reported in the Results section. Mice treated with Bean-
eIFNT (green squares) showed a decrease in mean antibody response to TMEV at the post-treatment time 
point (green broken line). The Bean-eMOPS mice (blue circles) had higher mean antibody titers at the 
post-treatment (broken blue line) time point. The differences in serum antibody levels to TMEV between 
the BeAn-eIFNT and Bean-eMOPS mice at the post-treatment time-point did not reach significance. PBS 
control mice did not have any titers for antibodies above baseline levels. Each point on the graph 
represents the mean OD reading for 12 mice within a group at the designated dilution and time-point. n=12 
per group OD=optical density 
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4.4. Discussion 
Mice infected with TMEV produce significant levels of virus-specific antibodies and 
numbers of virus-specific ASCs compared to non-infected mice. eIFNT treatment during TVID 
resulted in a slight decrease in humoral activity when compared to eMOPS-treated mice, as seen 
in a decrease in virus-specific ASC numbers within their spleens and a decrease in virus-specific 
antibodies in their sera. Although this decrease was modest, one must remember that the 
peripheral compartment is being tested rather than the actual site of disease pathology, which is 
within the CNS. The data generated from Br-IL and SC-IL isolations were inconclusive. 
Increased numbers of animals are needed to validate these findings since only six animals were 
used per group. This procedure is fraught with difficulty since it entails the removal of activated 
lymphocytes from the CNS parenchyma and a subsequent 24 h incubation period. The majority 
of the CNS-ILs recovered during the isolation were dead based on trypan blue dye exclusion. 
Thus, the actual numbers of cells that may have given a positive antibody response is unclear 
since it is possible that the most robust cells are those that are nearing the end of their life-cycle 
and these may be too delicate to survive the rigorous isolation techniques necessary for this 
assay system.  Future immunostaining procedures should more clearly define the cell types 
inhabiting the CNS of the BeAn-eIFNT and BeAn-eMOPS mice and allow for the evaluation of 
the number of ASCs within the parenchyma, although the antigen-specificity of these cells will 
be unattainable with this protocol. 
The slight decrease in post-treatment virus-specific serum antibody levels was not expected. 
One disease modifying mechanism of Type I IFN therapy is commonly held to be a shift from a 
Th1 to a Th2 type immune profile. The results of Section 3 refute this hypothesis as do the 
antibody data from this section (Figure 22). In fact, neither IL-4 nor IL-5 (data not shown) 
production was evident in any of the mice tested in Section 3. These results are in conflict with 
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previously published results (Pachner et al., 2007) indicating a high number of ASCs within the 
CNS during TVID. It is possible that the decrease in humoral response seen in the current studies 
reflect a direct down-regulation of B cells by the IFNT treatment rather than a bystander effect of 
a decrease in a Th1 response. This researcher theorizes that B-cells are being utilized within the 
current system as APCs and that down-regulation of B-cells results in down-regulation of 
pathological T-cells with the final outcome being a decrease in demyelinating pathology. To 
support this claim, researchers (Ghandi et al., 2008) have found B-cell activating factor (BAFF) 
to be a reliable biological marker for IFNB treatment in the serum of MS patients. The soluble 
form of BAFF is presumed to act as a down-regulator of B-cell activity. Treatment of MS 
patients with an antibody to delete B-cells, Rituximab, decreased disease progression by 50% 
over placebo controls, but total antibody concentration in patient serum did not decrease. 
(Hauser, 2008). Likewise, the removal of antibodies from MS patient sera by plasmapheresis has 
minimal benefit. Thus, it is plausible that the action of Type I IFN and Rituximab may be 
through the down-regulation of the B-cell as an APC. Since studies focusing on the B-cell are in 
their infancy, there is still much to learn about their place within MS disease pathology and 
exactly how one might exploit their position to ameliorate disease severity. 
 In summary, investigations to elucidate the humoral responses of the BeAn-eIFNT-
treated mice within this dissertation have been inadequate and further investigation is needed. 
The quantification of Th1 and Th2 serum cytokine levels will bolster this data and provide more 
information about the actual cytokine environment that exists within the BeAn-eIFNT mice 
compared to the BeAn-eMOPS mice during TVID. It is hypothesized that the serum cytokine 
levels within the BeAn-eIFNT mice will reflect an increase in Th2 cytokines which strengthens 
the trend of lower viral antibody titers observed in the present study in these mice compared to 
the BeAn-eMOPS mice.  Future investigations require that extra mice be added to the 
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experimental design for the quantification of viral load (by plaque assay) within the CNS of 
BeAn-eIFNT mice versus BeAn-eMOPS mice. A time-point series would be best, as mice could 
be terminated at different time-points post-treatment to quantify viral load within the CNS.  It is 
hypothesized that the decrease in serum antibodies reported in this study reflects a decrease in or 
the total clearance of the BeAn virus within the CNS of eIFNT-treated mice. The 
aforementioned investigations should verify the humoral data gathered within this study and may 
provide correlational data between serum antibody levels and viral load within the CNS of TVID 
mice during eIFNT treatment.  
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5. CONCLUSIONS 
 
 
Results of the current study demonstrate the effectiveness of eIFNT in the treatment of 
TVID. The efficacy of IFNT has been tested in the context of the EAE animal model of MS, in 
which animals are primed with myelin antigens to initiate demyelinating disease. However, an 
evaluation of the therapeutic value of IFNT has not been investigated in a virus-initiating model 
of demyelinating disease, such as TVID.  The fact that IFNT exerts an effect across species and 
that the toxicity associated with IFNT is far less than that associated with the other type I 
interferons, prompted investigations directed towards unraveling the value of IFNT as a highly 
desirable therapeutic agent.   
 The major finding to emerge from this dissertation is that BeAn-eIFNT-treated mice 
demonstrated a marked clinical improvement (a decrease of 1-2 points).  This is a novel finding 
amongst previous Type I IFN studies and the best verification of treatment efficacy.  The 
decrease in clinical score (disability) was reflected in a decrease in inflammation and the absence 
of demyelination (pathology) within the CNS of BeAn-eIFNT-treated animals. The tolerability 
of the treatment was also informative since an innovative method of delivery (encapsulation) 
was enlisted for these studies (Arenas-Gamboa et al., 2008). The encapsulation did not hinder 
IFNT release or usage (as demonstrated by disease attenuation) nor did it cause pathology within 
any organ systems. Likewise, the constant release of IFNT from the capsules did not raise the 
level of toxicity within the treated animals as evidenced by the lack of weight loss (a common 
side effect of toxicity in animals). The treatment did not appear to result in the production of 
neutralizing antibodies to IFNT either as reflected in the animals improving throughout the 8 
week treatment period. Thus, the disease modifying effects of IFNT did not appear to decrease 
as treatment progressed. This is an invaluable testament to the tolerability of IFNT since many 
MS patients develop neutralizing antibodies to the IFNB treatment which results in a decrease in 
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disease modification and the unwanted side effect of painful injection site reactions (Lublin and 
Reingold, 1996; Mehta et al., 1998) often leading to the cessation of therapy. Recent 
investigations of the pharmacogenomics of IFNB responses have elucidated which patients are 
biological responders to IFN therapy before precious time and money are wasted in an attempt to 
treat a patient that is an IFN non-responder (Van Baarsen et al., 2008). Additionally, ex vivo 
testing of peripheral blood lymphocytes is being evaluated (as was done in this dissertation) in 
order to predict treatment response to IFNB in MS patients (Wiesemann et al., 2008). Lastly, 
investigators have linked certain HLA alleles to the predisposition of a patient to produce 
neutralizing antibodies to IFNB during treatment (Barbosa et al., 2006; Hoffmann et al., 2008) 
before treatment begins.  
Based on the findings of this investigation, caution may be needed when interpreting the 
data from studies designed to predict a patient’s response to Type I IFN treatment. In the current 
study, animals responded with high and low cytokine secretory responses in vitro when 
stimulated with antigen, but both types of responders manifested clinical improvement when 
treated with eIFNT in vivo. It is not known from this study if the animals that were low secretory 
responders would have been low responders in a pre-treatment condition or if the low response 
was a manifestation of the eight week IFNT treatment regimen within this group of animals. 
Thus, until such a discrepancy in the data is resolved, caution should be used before decisions 
are made to exclude a patient from a Type I IFN treatment regimen. Since there are so few 
treatment options available to the MS patient, pre-screening that labels a patient as a non-
responder could have huge repercussions for future coverage of such a medication by that 
patient’s health insurance company. 
The second objective of this dissertation was to elucidate the mechanism of disease 
modification during eIFNT treatment. It was hypothesized that a shift in immune profile from a 
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Th1 to a Th2 response would be evidenced by the production of cytokines in virus-stimulated 
cultures from eIFNT treated mice. However, an increase in both Th1 and Th2 cytokines was 
observed. In fact, the two most abundantly produced cytokines in the current studies were TNFA 
and IFNG. These two cytokines are the hallmarks of pro-inflammatory responses and were not 
expected. However, it should be noted that these cytokines were produced in vitro in response to 
antigen stimulation by UV-inactivated BeAn virus for 72 h and were not detected in sera or CSF 
of mice. Additional investigations are currently underway to test the sera from these same mice 
(via Bio-Plex luminescence kits) to determine if there is a correlation between in vitro and in 
vivo produced cytokines. There is evidence in the literature that these two cytokines may have 
pleiotropic effects and that considering them as only detrimental to demyelinating pathology is 
short-sighted. Within the EAE model of MS, mice lacking TNF have an increased susceptibility 
to EAE, whereas the reconstitution of TNF within these mice reduces disease severity (Liu et al., 
1998). Additionally, TNF receptor 2 engagement was shown to promote remyelination through 
the proliferation of OPCs in a toxic model of demyelination (Arnett et al., 2001). Lastly, 
attempts to neutralize TNF in MS patients significantly enhanced disease severity (The 
Lenercept Multiple Sclerosis Study Group, 1999). Likewise, it has been shown in SJL/J mice 
that neutralizing IFNG with antibodies increases demyelination pathology (Rodriguez et al., 
1995) and IFNG knock-out mice exhibited increased demyelination and mortality when infected 
with avirulent strains of TMEV (Fiette et al., 1995).  Thus, the tendency to define a cytokine as 
detrimental or beneficial within a dynamic disease process, such as MS, is often too narrow to 
accommodate the pleiotropic behavior of many cytokines. Additionally, ex vivo data must be 
regarded as an indication of physiological conditions within the animal. Data gathered from sera, 
CSF, or CNS tissues should be enlisted whenever possible as data from these samples have more 
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merit since they provide information about the cytokine profile during the disease process at the 
time of data collection without additional experimental manipulation outside of the animal.  
 Results from the evaluation of humoral responses were surprising. It was hypothesized 
that there would be an increase in virus-specific antibodies and ASCs. The results refuted this 
hypothesis. There was a decrease in BeAn-specific antibody production and a very modest 
decrease in ASCs observed in the current studies. A search of the literature revealed no other 
studies that could support these conclusions. However, this is the first report of IFNT being used 
as a treatment of a virus-initiated demyelinating disease.  Other studies have tested the disease 
modifying effects of Type I IFNs within the EAE animal model of MS.  Thus, the current study 
may have elucidated a difference in disease modifying mechanism between these two animal 
models of MS. Within MS patients, it has been shown that IFNB treatment resulted in a decrease 
in serum levels of MS-associated retrovirus particles (MSRV). It is proposed that this could be a 
valuable biological marker for testing Type I IFN biological activity (Mameli et al., 2008). 
Likewise, MxA, a GTPase involved in anti-viral activity, is expressed after Type I IFN treatment 
and has been used as a biological marker in MS patients receiving IFNB therapy (Vallittu, 2007).  
Other anti-viral molecules, such as OAS and RNAse L, could be used to test the biological 
activity of IFNT within the current system which initiates demyelinating disease with a virus. 
These investigations could highlight how the response to a Type I IFN may be different within a 
demyelination model that includes viral infection as the initiator of disease. Such studies might 
also provide insight about how these anti-viral molecules are expressed during a condition of 
persistent infection, as is the case of TVID, and the way Type I IFN treatment may affect their 
patterns of expression. 
Altogether the data support the efficacy of the eIFNT treatment in the mice with TVID. 
Actual mechanisms of disease attenuation remain elusive at this time as mice exhibited a mixed 
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increase of Th1 and Th2 cytokines rather than the hypothesized shift from a Th1 to a Th2 
immune profile. Likewise, mice exhibited a modest decrease in virus-specific antibodies as well 
as the number virus-specific ASCs which also refute the hypothesized increase in these values 
due to an increase in Th2 immunity. A remarkable finding was the fact that immune cells 
derived from BeAn-eIFNT-treated mice appeared to be divided into two distinct types of 
biological responders although all of the mice responded to the in vivo treatment with eIFNT 
with a decrease in disease severity. It is hypothesized that this difference is a reflection of 
individual genetic variability in response to immune modulation which is surprising as mice used 
for these studies are in-bred and considered to be identical genetically. Obviously, immune 
modulation can proceed through different mechanisms and still provide the desired result of a 
decrease in disease progression and/or severity. However, this reality creates an added level of 
difficulty when one is trying to interpret biological data in order to determine whether a 
therapeutic regimen is efficacious within a patient population. 
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6. FUTURE DIRECTIONS 
 
The bimodal secretion pattern of cytokines produced by splenocytes from BeAn-eIFNT 
treated mice warrants further investigation. Three possible hypotheses are proposed: a) the 
high/low secretion from the splenocytes may reflect an animal’s phase of disease process when 
sampled for cytokine secretion, b) the high/low patterns of secretion may reflect variability upon 
chronic IFN receptor engagement, or c) the high/low patterns of secretion may be the result of 
different signaling pathways converging. 
The first possibility for bimodal secretion may reflect phase of the disease process. During 
immune modulation in the BeAn-TVID mice, some mice may resolve their inflammatory lesions 
within the CNS quicker than others within the same group. This could be reflected as an overall 
decrease in cell responsiveness during the ex vivo experimental conditions used within this study 
to evaluate cytokine secretion patterns and levels upon exposure to BeAn antigen. Thus, the low 
secretors may reflect animals that have achieved disease resolution and whose splenocytes are no 
longer responsive to antigen stimulation, whereas the higher secretors reflect animals that are 
still clearing the virus and resolving inflammation within the CNS and are still responsive to 
antigen stimulation. At this time, this possibility seems unlikely since the clinical score data from 
30 individual mice did not reflect a difference in recovery time as noted by the small SEMs 
among the data pool.  However, future investigations will track the improvement of each 
individual mouse more closely to rule out this possibility. 
 The second possibility for bimodal secretion may reflect the genetic variation within the 
individual mice to respond to constant IFN receptor engagement. It is possible that the constant 
presence of IFNT within the present system could lead to differences in response from the 
individual mice. Low cytokine secretors may reflect habituation of the IFN receptor and a lack of 
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response reflects a down-regulation of the IFN receptor or its signaling mechanisms. The 
habituation may occur in down-stream components of the signaling pathway and may actually be 
induced by inhibitors of signaling such as SOCS (suppressors of cytokine signaling) molecules. 
Flow cytometric analysis of receptor numbers and signaling components of the splenocytes of 
low and high responders could answer such questions.  
 Lastly, the majority of cytokines up-regulated in this study use the JAK-STAT pathway. 
Thus, the constant presence of IFNT may affect the signaling of other cytokines in a positive or 
negative way depending on the individual mouse variation. This possibility could also be 
resolved with flow cytometric analysis of the various STATs being used in high and low 
cytokine secretors. Microarray analysis or high throughput gene sequencing may also prove 
beneficial in sorting out the broad range of genetic influence on cytokine signaling pathways 
during constant Type I IFN stimulation. 
Overall, the cytokine findings warrant further investigations that: a) utilize purified cell 
cultures to better identify which cell type is producing each cytokine in response to antigen 
stimulation; b) examine intracellular signaling pathways to establish a difference between the 
high and low responses in cytokine production observed in these studies; and c) employ 
molecular techniques, such as microarray technology or high throughput gene sequencing, to 
pinpoint genomic differences in relation to biological response. 
Future investigations should include the use of plaque assays to define levels of BeAn 
activity in mice treated with eIFNT during TVID. Additionally, mice should be evaluated at pre-
treatment time-points for BeAn load as well as lesion load to assess these two parameters prior to 
treatment, setting a baseline for how far the disease has progressed before treatment begins. This 
data would demonstrate a direct effect of systemic IFNT treatment on CNS disease modification 
during TVID. 
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Lastly, future investigations will include studies designed to test the effect of eIFNT on 
CNS demyelinating pathology at earlier time-points in order to evaluate the mechanism of lesion 
resolution. The current study “missed” this aspect of eIFNT treatment because resolution of the 
lesions was not hypothesized.  Future studies will evaluate the CNS of BeAn-eIFNT mice at 2-4 
weeks post-treatment in order to catch a glimpse of the mechanism of lesion resolution enlisted 
during IFNT treatment. Tissues will be collected and evaluated with electron microscopy and 
immunohistochemistry to characterize cell type, myelin integrity, and oligodendrocyte 
maturation. Current therapies for MS slow disease progression and lengthen the amount of time 
it takes to reach the secondary progressive stage of the disease. A therapy that halts disease 
progression, restores function, and resolves demyelinating lesions is what is needed. In this 
study, IFNT provided those benefits to animals during TVID. 
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